<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">21455303</article-id><article-id pub-id-type="pmc">3063788</article-id><article-id pub-id-type="publisher-id">PONE-D-10-04521</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0018204</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biology</subject><subj-group><subject>Computational Biology</subject><subj-group><subject>Population Modeling</subject><subj-group><subject>Infectious Disease Modeling</subject></subj-group></subj-group><subj-group><subject>Evolutionary Modeling</subject></subj-group></subj-group><subj-group><subject>Microbiology</subject><subj-group><subject>Virology</subject><subj-group><subject>Viral Transmission and Infection</subject><subj-group><subject>Viral Load</subject></subj-group></subj-group><subj-group><subject>Antivirals</subject><subject>Immunodeficiency Viruses</subject><subject>Viral Persistence and Latency</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Computer Science</subject><subj-group><subject>Computerized Simulations</subject></subj-group></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine</subject><subj-group><subject>Infectious Diseases</subject><subj-group><subject>Viral Diseases</subject><subj-group><subject>HIV</subject></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>HIV Quasispecies Dynamics during Pro-Active Treatment Switching: Impact on Multi-Drug Resistance and Resistance Archiving in Latent Reservoirs</article-title><alt-title alt-title-type="running-head">HIV Dynamics during Pro-Active Treatment Switching</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>von Kleist</surname><given-names>Max</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>&#x0002a;</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Menz</surname><given-names>Stephan</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Stocker</surname><given-names>Hartmut</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Arasteh</surname><given-names>Keikawus</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Sch&#x000fc;tte</surname><given-names>Christof</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Huisinga</surname><given-names>Wilhelm</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>
<addr-line>Department of Mathematics and Computer Science, Freie Universit&#x000e4;t, Berlin, Germany</addr-line>
</aff><aff id="aff2">
<label>2</label>
<addr-line>Department of Gastroenterology and Infectious Diseases, Vivantes-Auguste-Viktoria-Klinikum, Berlin, Germany</addr-line>
</aff><aff id="aff3">
<label>3</label>
<addr-line>Hamilton Institute, National University of Ireland, Maynooth, Republic of Ireland</addr-line>
</aff><aff id="aff4">
<label>4</label>
<addr-line>Institute of Mathematics, University of Potsdam, Potsdam, Germany</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name><surname>Poon</surname><given-names>Art</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">British Columbia Centre for Excellence in HIV/AIDS, Canada</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>vkleist@zedat.fu-berlin.de</email></corresp><fn fn-type="con"><p>Conceived and designed the experiments: MvK. Performed the experiments: MvK SM. Analyzed the data: MvK SM HS KA WH CS. Wrote the paper: MvK HS KA WH CS.</p></fn></author-notes><pub-date pub-type="collection"><year>2011</year></pub-date><pub-date pub-type="epub"><day>24</day><month>3</month><year>2011</year></pub-date><volume>6</volume><issue>3</issue><elocation-id>e18204</elocation-id><history><date date-type="received"><day>4</day><month>11</month><year>2010</year></date><date date-type="accepted"><day>27</day><month>2</month><year>2011</year></date></history><permissions><copyright-statement>von Kleist et al.</copyright-statement><copyright-year>2011</copyright-year><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><abstract><p>The human immunodeficiency virus (HIV) can be suppressed by highly active anti-retroviral therapy (HAART) in the majority of infected patients. Nevertheless, treatment interruptions inevitably result in viral rebounds from persistent, latently infected cells, necessitating lifelong treatment. Virological failure due to resistance development is a frequent event and the major threat to treatment success. Currently, it is recommended to change treatment after the confirmation of virological failure. However, at the moment virological failure is detected, drug resistant mutants already replicate in great numbers. They infect numerous cells, many of which will turn into latently infected cells. This pool of cells represents an archive of resistance, which has the potential of limiting future treatment options. The objective of this study was to design a treatment strategy for treatment-naive patients that decreases the likelihood of early treatment failure and preserves future treatment options. We propose to apply a single, pro-active treatment switch, following a period of treatment with an induction regimen. The main goal of the <italic>induction regimen</italic> is to decrease the abundance of randomly generated mutants that confer resistance to the <italic>maintenance regimen</italic>, thereby increasing subsequent treatment success. Treatment is switched before the overgrowth and archiving of mutant strains that carry resistance against the <italic>induction regimen</italic> and would limit its future re-use. <italic>In silico</italic> modelling shows that an optimal trade-off is achieved by switching treatment at <inline-formula><inline-graphic xlink:href="pone.0018204.e001.jpg" mimetype="image"/></inline-formula> days after the initiation of antiviral therapy. Evaluation of the proposed treatment strategy demonstrated significant improvements in terms of resistance archiving and virological response, as compared to conventional HAART. While continuous pro-active treatment alternation improved the clinical outcome in a randomized trial, our results indicate that a similar improvement might also be reached after a single pro-active treatment switch. The clinical validity of this finding, however, remains to be shown by a corresponding trial.</p></abstract><counts><page-count count="12"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>In 1996, the tremendous clinical success of highly active antiretroviral therapy had led many researchers to believe that the eradication of HIV would be feasible. However, it was soon realized that inducible pro-virus persists in latently infected cells despite ongoing therapy and that the latent reservoir prevents HIV eradication within the patients lifetime <xref rid="pone.0018204-Finzi1" ref-type="bibr">[1]</xref>&#x02013;<xref rid="pone.0018204-Chun2" ref-type="bibr">[6]</xref>.</p><p>Latent infection is established when <inline-formula><inline-graphic xlink:href="pone.0018204.e002.jpg" mimetype="image"/></inline-formula> T-lymphoblasts containing integrated provirus <xref rid="pone.0018204-Chun1" ref-type="bibr">[5]</xref>, <xref rid="pone.0018204-Chun3" ref-type="bibr">[7]</xref> escape both immune effector mechanisms and the cytopathic effects of the virus and revert to a resting memory state <xref rid="pone.0018204-Pierson1" ref-type="bibr">[8]</xref>. Besides preventing eradication of HIV, the latent reservoir also serves as a memory of any virus species replicating during the course of HIV infection <xref rid="pone.0018204-Siliciano1" ref-type="bibr">[9]</xref>, <xref rid="pone.0018204-Lambotte1" ref-type="bibr">[10]</xref>, including drug resistant variants. The contents of this archive of resistance are strong predictors of future treatment failure <xref rid="pone.0018204-Siliciano1" ref-type="bibr">[9]</xref>, <xref rid="pone.0018204-Reekie1" ref-type="bibr">[11]</xref>.</p><p>Despite the impressive improvement of antiviral therapy, many patients still experience virological failure caused by the selection of drug resistant virus populations. Current guidelines recommend changing treatment after the confirmation of virological failure. However, in the face of the rapid viral turnover this approach could be sub-optimal <xref rid="pone.0018204-Ho1" ref-type="bibr">[12]</xref>. Changing therapy after the appearance of drug resistant mutants will (i) allow the resistant viral population size to expand and evolve and (ii) lead to an archivation of resistant viral strains. An optimal treatment strategy should therefore prevent viral relapse with drug resistant strains and, more importantly, prevent drug resistant mutants from establishing latent infection.</p><p>Induction-maintenance (IM) approaches are used for the treatment of a growing number of infectious- and neoplastic diseases <xref rid="pone.0018204-Blumberg1" ref-type="bibr">[13]</xref>&#x02013;<xref rid="pone.0018204-Zimmerli1" ref-type="bibr">[15]</xref>. Typically, patients start with an intensified induction regimen (composed of a number of potent and potentially toxic drugs), which will subsequently be replaced by a maintenance regimen (composed of a smaller number of less toxic drugs) <xref rid="pone.0018204-Curlin1" ref-type="bibr">[16]</xref>. However, patients treated with a large number of drugs are particularly vulnerable to drug interactions <xref rid="pone.0018204-Catanzaro1" ref-type="bibr">[17]</xref> and adverse side effects that complicate HIV therapy and seriously undermine the success of clinical management <xref rid="pone.0018204-Carr1" ref-type="bibr">[18]</xref>.</p><p>Another approach to overcome the development of resistance is to alternate antiretroviral therapy <xref rid="pone.0018204-DAmato1" ref-type="bibr">[19]</xref>. This strategy has been shown to significantly delay virological failure <xref rid="pone.0018204-MartinezPicado1" ref-type="bibr">[20]</xref>, <xref rid="pone.0018204-Negredo1" ref-type="bibr">[21]</xref>, yet it is flawed by its high psychological and physical burden <xref rid="pone.0018204-Sherr1" ref-type="bibr">[22]</xref>.</p><p>We propose an approach that combines the advantages of conventional IM- and treatment alternation strategies, but minimizes their inherent disadvantages. We suggest a single, pro-active treatment switch from an inducer drug combination to a maintenance combination. The inducer drug combination should rapidly lower the viral population size and eliminate resistant mutants. Subsequently, it will be replaced by a maintenance drug regimen with a completely different resistance profile, before drug resistant strains are archived.</p><p>We have previously introduced a novel model of virus dynamics and adaptation <xref rid="pone.0018204-vonKleist1" ref-type="bibr">[23]</xref>, which allows us to consider the distinct molecular effects of all novel (and some developmental) HIV drugs. In this article, we present a novel mathematical concept, which prevents the emergence of drug resistance in each individual realization (virtual patient) of the model by switching between therapies. Utilizing this concept, we deduce a distribution of (individual) switching-times, which we use to determine a single fixed duration for the induction therapy, which increases the treatment success probability in the whole virtual patient population and which minimizes the risk for resistance to become archived in the latent reservoir. Finally, the performance of this novel induction-maintenance-strategy is evaluated against conventional HAART therapy.</p></sec><sec id="s2"><title>Results</title><sec id="s2a"><title>Virus dynamics model</title><p>We have extended the existing viral dynamics model, described in <xref rid="pone.0018204-vonKleist1" ref-type="bibr">[23]</xref>, for the compartment of very long lived, latently infected T-cells <inline-formula><inline-graphic xlink:href="pone.0018204.e003.jpg" mimetype="image"/></inline-formula> (<xref ref-type="fig" rid="pone-0018204-g001">Fig. 1</xref> and <xref ref-type="sec" rid="s4">
<italic>Materials and Methods</italic>
</xref> section), which are believed to prevent eradication of HIV <xref rid="pone.0018204-Panel1" ref-type="bibr">[24]</xref> and to lead to the archiving of drug resistance <xref rid="pone.0018204-Siliciano1" ref-type="bibr">[9]</xref>, <xref rid="pone.0018204-Lambotte1" ref-type="bibr">[10]</xref>.</p><fig id="pone-0018204-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0018204.g001</object-id><label>Figure 1</label><caption><title>Extended virus dynamics-, mutation- and drug interference model.</title><p>Target cells (<inline-formula><inline-graphic xlink:href="pone.0018204.e004.jpg" mimetype="image"/></inline-formula>) can become successfully infected by infective virus <inline-formula><inline-graphic xlink:href="pone.0018204.e005.jpg" mimetype="image"/></inline-formula> with infection rate constants <inline-formula><inline-graphic xlink:href="pone.0018204.e006.jpg" mimetype="image"/></inline-formula> and <inline-formula><inline-graphic xlink:href="pone.0018204.e007.jpg" mimetype="image"/></inline-formula>, respectively, creating early infected cells <inline-formula><inline-graphic xlink:href="pone.0018204.e008.jpg" mimetype="image"/></inline-formula> and <inline-formula><inline-graphic xlink:href="pone.0018204.e009.jpg" mimetype="image"/></inline-formula>. Infection can also be unsuccessful after the step of viral fusion (rate constant <inline-formula><inline-graphic xlink:href="pone.0018204.e010.jpg" mimetype="image"/></inline-formula> and <inline-formula><inline-graphic xlink:href="pone.0018204.e011.jpg" mimetype="image"/></inline-formula>), eliminating the virus and rendering the cell uninfected. Early infected cells <inline-formula><inline-graphic xlink:href="pone.0018204.e012.jpg" mimetype="image"/></inline-formula> and <inline-formula><inline-graphic xlink:href="pone.0018204.e013.jpg" mimetype="image"/></inline-formula> can also destroy essential viral proteins or DNA prior to integration, returning the cell to an uninfected stage. The genomic viral DNA can become integrated with rate constants <inline-formula><inline-graphic xlink:href="pone.0018204.e014.jpg" mimetype="image"/></inline-formula> and <inline-formula><inline-graphic xlink:href="pone.0018204.e015.jpg" mimetype="image"/></inline-formula> creating post-integration, infected cells <inline-formula><inline-graphic xlink:href="pone.0018204.e016.jpg" mimetype="image"/></inline-formula> and <inline-formula><inline-graphic xlink:href="pone.0018204.e017.jpg" mimetype="image"/></inline-formula>. The latently infected cell type <inline-formula><inline-graphic xlink:href="pone.0018204.e018.jpg" mimetype="image"/></inline-formula> does not express viral genes, but can become activated with rate <inline-formula><inline-graphic xlink:href="pone.0018204.e019.jpg" mimetype="image"/></inline-formula>, transforming this cell into a productively infected T-cell <inline-formula><inline-graphic xlink:href="pone.0018204.e020.jpg" mimetype="image"/></inline-formula>. Virus producing cells <inline-formula><inline-graphic xlink:href="pone.0018204.e021.jpg" mimetype="image"/></inline-formula> release new infectious- and non infectious virus <inline-formula><inline-graphic xlink:href="pone.0018204.e022.jpg" mimetype="image"/></inline-formula> and <inline-formula><inline-graphic xlink:href="pone.0018204.e023.jpg" mimetype="image"/></inline-formula> with rate constants <inline-formula><inline-graphic xlink:href="pone.0018204.e024.jpg" mimetype="image"/></inline-formula> and <inline-formula><inline-graphic xlink:href="pone.0018204.e025.jpg" mimetype="image"/></inline-formula>, respectively. Phenotypic mutation occurs at the stage of viral genomic integration <inline-formula><inline-graphic xlink:href="pone.0018204.e026.jpg" mimetype="image"/></inline-formula> (see <xref rid="pone.0018204-vonKleist1" ref-type="bibr">[23]</xref>). All cellular compartments <inline-formula><inline-graphic xlink:href="pone.0018204.e027.jpg" mimetype="image"/></inline-formula> can get destroyed by the immune system with respective rate constants <inline-formula><inline-graphic xlink:href="pone.0018204.e028.jpg" mimetype="image"/></inline-formula> and the free virus (infectious and non-infectious) gets cleared with rate constant <inline-formula><inline-graphic xlink:href="pone.0018204.e029.jpg" mimetype="image"/></inline-formula> (not shown in the illustration). The site of drug interference with the replicative cycle of HIV is indicated by blue bars for the respective drug classes (NRTIs, NNRTIs, FIs, CCR5-inhibitors, INIs, PIs, and maturation inhibitors).</p></caption><graphic xlink:href="pone.0018204.g001"/></fig><p>Briefly, the virus dynamics model (<xref ref-type="fig" rid="pone-0018204-g001">Fig. 1</xref>) comprises T-cells, macrophages, free non-infectious virus (<inline-formula><inline-graphic xlink:href="pone.0018204.e030.jpg" mimetype="image"/></inline-formula>, respectively), free infectious virus of mutant strain <inline-formula><inline-graphic xlink:href="pone.0018204.e031.jpg" mimetype="image"/></inline-formula>, and five types of infected cells belonging to mutant strain <inline-formula><inline-graphic xlink:href="pone.0018204.e032.jpg" mimetype="image"/></inline-formula>: infected T-cells and macrophages <italic>prior</italic> to proviral genomic integration (<inline-formula><inline-graphic xlink:href="pone.0018204.e033.jpg" mimetype="image"/></inline-formula> and <inline-formula><inline-graphic xlink:href="pone.0018204.e034.jpg" mimetype="image"/></inline-formula>, respectively) and infected T-cells and macrophages <italic>after</italic> proviral genomic integration (<inline-formula><inline-graphic xlink:href="pone.0018204.e035.jpg" mimetype="image"/></inline-formula> and <inline-formula><inline-graphic xlink:href="pone.0018204.e036.jpg" mimetype="image"/></inline-formula>, respectively). The latently infected cell type <inline-formula><inline-graphic xlink:href="pone.0018204.e037.jpg" mimetype="image"/></inline-formula> does not express viral genes, but can become activated with rate <inline-formula><inline-graphic xlink:href="pone.0018204.e038.jpg" mimetype="image"/></inline-formula>, transforming this cell into a virus producing post-integration infected T-cell <inline-formula><inline-graphic xlink:href="pone.0018204.e039.jpg" mimetype="image"/></inline-formula>. The average rates of change of the different species are displayed in the <xref ref-type="sec" rid="s4">
<italic>Materials and Methods</italic>
</xref> section. All parameter values have been chosen according to previous studies and are displayed in <xref ref-type="table" rid="pone-0018204-t001">Table 1</xref>. Since some viral strains are present only in very low copy numbers, we used a hybrid stochastic-deterministic approach <xref rid="pone.0018204-Alfonsi1" ref-type="bibr">[25]</xref> to perform simulations (see <xref ref-type="sec" rid="s4">
<italic>Materials and Methods</italic>
</xref> section for details).</p><table-wrap id="pone-0018204-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0018204.t001</object-id><label>Table 1</label><caption><title>Model parameters generally used in simulations.</title></caption><alternatives><graphic id="pone-0018204-t001-1" xlink:href="pone.0018204.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Param.</td><td align="left" rowspan="1" colspan="1">Value</td><td align="left" rowspan="1" colspan="1">Ref.</td><td align="left" rowspan="1" colspan="1">Param.</td><td align="left" rowspan="1" colspan="1">Value</td><td align="left" rowspan="1" colspan="1">Ref.</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<inline-formula><inline-graphic xlink:href="pone.0018204.e040.jpg" mimetype="image"/></inline-formula>
</td><td align="left" rowspan="1" colspan="1">
<inline-formula><inline-graphic xlink:href="pone.0018204.e041.jpg" mimetype="image"/></inline-formula>
</td><td align="left" rowspan="1" colspan="1">
<xref rid="pone.0018204-Wei1" ref-type="bibr">[64]</xref>
</td><td align="left" rowspan="1" colspan="1">
<inline-formula><inline-graphic xlink:href="pone.0018204.e042.jpg" mimetype="image"/></inline-formula>
</td><td align="left" rowspan="1" colspan="1">
<inline-formula><inline-graphic xlink:href="pone.0018204.e043.jpg" mimetype="image"/></inline-formula>
</td><td align="left" rowspan="1" colspan="1">
<xref rid="pone.0018204-Sedaghat2" ref-type="bibr">[65]</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<inline-formula><inline-graphic xlink:href="pone.0018204.e044.jpg" mimetype="image"/></inline-formula>
</td><td align="left" rowspan="1" colspan="1">0.02</td><td align="left" rowspan="1" colspan="1">
<xref rid="pone.0018204-Sedaghat2" ref-type="bibr">[65]</xref>
</td><td align="left" rowspan="1" colspan="1">
<inline-formula><inline-graphic xlink:href="pone.0018204.e045.jpg" mimetype="image"/></inline-formula>
</td><td align="left" rowspan="1" colspan="1">0.0069</td><td align="left" rowspan="1" colspan="1">
<xref rid="pone.0018204-Sedaghat2" ref-type="bibr">[65]</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<inline-formula><inline-graphic xlink:href="pone.0018204.e046.jpg" mimetype="image"/></inline-formula>
</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">
<xref rid="pone.0018204-Markowitz1" ref-type="bibr">[36]</xref>
</td><td align="left" rowspan="1" colspan="1">
<inline-formula><inline-graphic xlink:href="pone.0018204.e047.jpg" mimetype="image"/></inline-formula>
</td><td align="left" rowspan="1" colspan="1">0.09</td><td align="left" rowspan="1" colspan="1">
<xref rid="pone.0018204-vonKleist1" ref-type="bibr">[23]</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<inline-formula><inline-graphic xlink:href="pone.0018204.e048.jpg" mimetype="image"/></inline-formula>
</td><td align="left" rowspan="1" colspan="1">23</td><td align="left" rowspan="1" colspan="1">
<xref rid="pone.0018204-Markowitz1" ref-type="bibr">[36]</xref>
</td><td align="left" rowspan="1" colspan="1">
<inline-formula><inline-graphic xlink:href="pone.0018204.e049.jpg" mimetype="image"/></inline-formula>
</td><td align="left" rowspan="1" colspan="1">
<inline-formula><inline-graphic xlink:href="pone.0018204.e050.jpg" mimetype="image"/></inline-formula>
</td><td align="left" rowspan="1" colspan="1">
<xref rid="pone.0018204-Curlin1" ref-type="bibr">[16]</xref>, <xref rid="pone.0018204-Callaway1" ref-type="bibr">[66]</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<inline-formula><inline-graphic xlink:href="pone.0018204.e051.jpg" mimetype="image"/></inline-formula>
</td><td align="left" rowspan="1" colspan="1">0.35</td><td align="left" rowspan="1" colspan="1">
<xref rid="pone.0018204-Koelsch1" ref-type="bibr">[67]</xref>, <xref rid="pone.0018204-Zhou1" ref-type="bibr">[68]</xref>
</td><td align="left" rowspan="1" colspan="1">
<inline-formula><inline-graphic xlink:href="pone.0018204.e052.jpg" mimetype="image"/></inline-formula>
</td><td align="left" rowspan="1" colspan="1">0.0035</td><td align="left" rowspan="1" colspan="1">
<xref rid="pone.0018204-vonKleist1" ref-type="bibr">[23]</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<inline-formula><inline-graphic xlink:href="pone.0018204.e053.jpg" mimetype="image"/></inline-formula>
</td><td align="left" rowspan="1" colspan="1">
<inline-formula><inline-graphic xlink:href="pone.0018204.e054.jpg" mimetype="image"/></inline-formula>
</td><td align="left" rowspan="1" colspan="1">
<xref rid="pone.0018204-Callaway1" ref-type="bibr">[66]</xref>
</td><td align="left" rowspan="1" colspan="1">
<inline-formula><inline-graphic xlink:href="pone.0018204.e055.jpg" mimetype="image"/></inline-formula>
</td><td align="left" rowspan="1" colspan="1">
<inline-formula><inline-graphic xlink:href="pone.0018204.e056.jpg" mimetype="image"/></inline-formula>
</td><td align="left" rowspan="1" colspan="1">
<xref rid="pone.0018204-Callaway1" ref-type="bibr">[66]</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<inline-formula><inline-graphic xlink:href="pone.0018204.e057.jpg" mimetype="image"/></inline-formula>
</td><td align="left" rowspan="1" colspan="1">
<inline-formula><inline-graphic xlink:href="pone.0018204.e058.jpg" mimetype="image"/></inline-formula>
</td><td align="left" rowspan="1" colspan="1">
<xref rid="pone.0018204-Mansky1" ref-type="bibr">[42]</xref>
</td><td align="left" rowspan="1" colspan="1">
<inline-formula><inline-graphic xlink:href="pone.0018204.e059.jpg" mimetype="image"/></inline-formula>
</td><td align="left" rowspan="1" colspan="1">0.33</td><td align="left" rowspan="1" colspan="1">
<xref rid="pone.0018204-Zhou1" ref-type="bibr">[68]</xref>, <xref rid="pone.0018204-Pierson2" ref-type="bibr">[69]</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<inline-formula><inline-graphic xlink:href="pone.0018204.e060.jpg" mimetype="image"/></inline-formula>
</td><td align="left" rowspan="1" colspan="1">0.35</td><td align="left" rowspan="1" colspan="1">
<xref rid="pone.0018204-Zhou1" ref-type="bibr">[68]</xref>
</td><td align="left" rowspan="1" colspan="1">
<inline-formula><inline-graphic xlink:href="pone.0018204.e061.jpg" mimetype="image"/></inline-formula>
</td><td align="left" rowspan="1" colspan="1">0.07</td><td align="left" rowspan="1" colspan="1">
<xref rid="pone.0018204-vonKleist1" ref-type="bibr">[23]</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<inline-formula><inline-graphic xlink:href="pone.0018204.e062.jpg" mimetype="image"/></inline-formula>
</td><td align="left" rowspan="1" colspan="1">
<inline-formula><inline-graphic xlink:href="pone.0018204.e063.jpg" mimetype="image"/></inline-formula>
</td><td align="left" rowspan="1" colspan="1">
<xref rid="pone.0018204-Sedaghat1" ref-type="bibr">[49]</xref>
</td><td align="left" rowspan="1" colspan="1">
<inline-formula><inline-graphic xlink:href="pone.0018204.e064.jpg" mimetype="image"/></inline-formula>
</td><td align="left" rowspan="1" colspan="1">
<inline-formula><inline-graphic xlink:href="pone.0018204.e065.jpg" mimetype="image"/></inline-formula>
</td><td align="left" rowspan="1" colspan="1">
<xref rid="pone.0018204-vonKleist1" ref-type="bibr">[23]</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<inline-formula><inline-graphic xlink:href="pone.0018204.e066.jpg" mimetype="image"/></inline-formula>
</td><td align="left" rowspan="1" colspan="1">1000</td><td align="left" rowspan="1" colspan="1">
<xref rid="pone.0018204-Sedaghat2" ref-type="bibr">[65]</xref>
</td><td align="left" rowspan="1" colspan="1">
<inline-formula><inline-graphic xlink:href="pone.0018204.e067.jpg" mimetype="image"/></inline-formula>
</td><td align="left" rowspan="1" colspan="1">100</td><td align="left" rowspan="1" colspan="1">
<xref rid="pone.0018204-Sedaghat2" ref-type="bibr">[65]</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<inline-formula><inline-graphic xlink:href="pone.0018204.e068.jpg" mimetype="image"/></inline-formula>
</td><td align="left" rowspan="1" colspan="1">0.67</td><td align="left" rowspan="1" colspan="1">
<xref rid="pone.0018204-vonKleist1" ref-type="bibr">[23]</xref>
</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt101"><label/><p>All parameters refer to the wildtype <inline-formula><inline-graphic xlink:href="pone.0018204.e069.jpg" mimetype="image"/></inline-formula> in the absence of drug treatment <inline-formula><inline-graphic xlink:href="pone.0018204.e070.jpg" mimetype="image"/></inline-formula>. All parameters in units [1/day], except <inline-formula><inline-graphic xlink:href="pone.0018204.e071.jpg" mimetype="image"/></inline-formula>, <inline-formula><inline-graphic xlink:href="pone.0018204.e072.jpg" mimetype="image"/></inline-formula>, <inline-formula><inline-graphic xlink:href="pone.0018204.e073.jpg" mimetype="image"/></inline-formula> (unit less) and <inline-formula><inline-graphic xlink:href="pone.0018204.e074.jpg" mimetype="image"/></inline-formula> in <inline-formula><inline-graphic xlink:href="pone.0018204.e075.jpg" mimetype="image"/></inline-formula>. <inline-formula><inline-graphic xlink:href="pone.0018204.e076.jpg" mimetype="image"/></inline-formula>, <inline-formula><inline-graphic xlink:href="pone.0018204.e077.jpg" mimetype="image"/></inline-formula>
<xref rid="pone.0018204-vonKleist1" ref-type="bibr">[23]</xref>.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2b"><title>Treatment change before virological failure</title><p>Currently, changes of antiretroviral treatment regimes are largely triggered by virological failure or toxicity. In <xref ref-type="fig" rid="pone-0018204-g002">Fig. 2A</xref>, we show the simulated viral load in the case of first line treatment failure. The corresponding population dynamics of HIV are shown in <xref ref-type="fig" rid="pone-0018204-g002">Fig. 2B</xref>. During first line treatment failure, resistant mutants (green- and cyan colored lines in <xref ref-type="fig" rid="pone-0018204-g002">Fig. 2B</xref>) are selected from the quasi-species population and quickly evolve into the dominant virus population, leading to viral rebound. While the total virus population is temporarily shrinking, mutants that confer resistance against a potential follow-up treatment (red line, dark grey shaded area in <xref ref-type="fig" rid="pone-0018204-g002">Fig. 2B</xref>) are depleted (possibly eradicated). However, during viral rebound the total viral population re-expands and consequently erroneous reverse transcription generates novel mutants that can confer resistance against a second line therapy. Once the viral population size has been restored, the second line therapy, although composed of entirely different drugs, is as likely to fail as before the initiation of first line therapy. Furthermore, it is likely that drug resistant viral strains become archived while they dominate the viral population (light grey shaded area in <xref ref-type="fig" rid="pone-0018204-g002">Fig. 2B</xref>).</p><fig id="pone-0018204-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0018204.g002</object-id><label>Figure 2</label><caption><title>Abundance of viral mutants during first-line treatment failure and during proposed induction-maintenance strategy.</title><p>A: Plasma virus load during first line treatment failure (blue line). B: Total abundance of distinct viral mutants during first-line treatment failure. C: Plasma virus load (blue line) during proposed induction-maintenance strategy with switch between induction- and maintenance treatment at 80 days (vertical dashed line). D: Total abundance of distinct viral mutants during proposed induction-maintenance strategy. The magenta line denotes the abundance of wildtype virus. Green- and cyan lines denote the abundance of mutants that are part-resistant against the first line regimen (resistant against two out of three drugs) and mutants that are fully resistant against the first line regimen, respectively. The red lines denote the abundance of all mutants, which are part-resistant against a second line treatment. The area under the red line is highlighted by the dark grey shaded area, to stress the negative impact of these mutants on the success of a second line regimen. The light shaded area in panel B indicates that resistant mutants are more abundant than the wildtype and therefore highlights when drug resistance archiving in latently infected cells takes place. The simulations were performed by assuming 70&#x00025; drug efficacy <inline-formula><inline-graphic xlink:href="pone.0018204.e078.jpg" mimetype="image"/></inline-formula> and a fitness loss <inline-formula><inline-graphic xlink:href="pone.0018204.e079.jpg" mimetype="image"/></inline-formula> of 20&#x00025; per drug resistance mutation. Furthermore, it was assumed that a single point mutation can confer absolute resistance to a single drug.</p></caption><graphic xlink:href="pone.0018204.g002"/></fig><p>In <xref ref-type="fig" rid="pone-0018204-g002">Fig. 2C</xref>, we show the viral load dynamics during the proposed induction-maintenance therapy. The corresponding population dynamics of HIV are shown in <xref ref-type="fig" rid="pone-0018204-g002">Fig. 2D</xref>. The inducer combination reduces the viral load (see <xref ref-type="fig" rid="pone-0018204-g002">Fig. 2C</xref>). However, treatment is changed (vertical dashed black line) to the maintenance combination, before resistant strains (green and cyan line in <xref ref-type="fig" rid="pone-0018204-g002">Fig. 2D</xref>) can become more abundant than the wildtype (magenta line in <xref ref-type="fig" rid="pone-0018204-g002">Fig. 2D</xref>). Therefore, at the time of treatment change (vertical dashed black line in <xref ref-type="fig" rid="pone-0018204-g002">Fig. 2D</xref>), total virus has been decreased and mutants that confer resistance to the maintenance therapy (red line, dark grey shaded area in <xref ref-type="fig" rid="pone-0018204-g002">Fig. 2D</xref>) are likely to be eradicated, which improves the probability to achieve durable virological suppression with the maintenance therapy. With this strategy, the abundance of the wildtype is larger than the abundance of drug-resistant mutants, which lowers the probability that drug resistance enters the latent reservoir (light grey shaded area is absent in <xref ref-type="fig" rid="pone-0018204-g002">Fig. 2D</xref>).</p><p>In order to determine the optimal time point for switching from inducer- to maintenance- drug combinations, <inline-formula><inline-graphic xlink:href="pone.0018204.e080.jpg" mimetype="image"/></inline-formula>, we first determined relevant sets of parameters for (i) the <italic>in vivo</italic> efficacy <inline-formula><inline-graphic xlink:href="pone.0018204.e081.jpg" mimetype="image"/></inline-formula> of each utilized drug <inline-formula><inline-graphic xlink:href="pone.0018204.e082.jpg" mimetype="image"/></inline-formula> against the wildtype <inline-formula><inline-graphic xlink:href="pone.0018204.e083.jpg" mimetype="image"/></inline-formula> and (ii) the <italic>in vivo</italic> fitness loss that is associated with resistance development <inline-formula><inline-graphic xlink:href="pone.0018204.e084.jpg" mimetype="image"/></inline-formula> (shown in <xref ref-type="supplementary-material" rid="pone.0018204.s002">Table S1</xref>), since the corresponding <italic>in vivo</italic> parameters are known to vary substantially between different patients, e.g. <xref rid="pone.0018204-Fabbiani1" ref-type="bibr">[26]</xref>. For simulation purposes, we assumed that a single point mutation is sufficient to create high-level resistance (99&#x00025;) to a single drug. This is somewhat a worst-case assumption, but is justified for a number of drugs, see e.g. <xref rid="pone.0018204-Clavel1" ref-type="bibr">[27]</xref>, <xref rid="pone.0018204-Clavel2" ref-type="bibr">[28]</xref>. Relevant clinical failure rates after one year in previously treatment-naive patients, who receive HAART in a clinical trial setting, are <inline-formula><inline-graphic xlink:href="pone.0018204.e085.jpg" mimetype="image"/></inline-formula>
<xref rid="pone.0018204-Riddler1" ref-type="bibr">[29]</xref>, (see <xref ref-type="supplementary-material" rid="pone.0018204.s002">Table S1</xref>).</p><p>We then use an algorithm that automatically switches from inducer- to maintenance drug combination, minimizing virological failure for each realization (virtual patient), respectively. A histogram of the derived (individual) switching times from a total of 6000 simulations is shown in <xref ref-type="fig" rid="pone-0018204-g003">Fig. 3</xref>. Based on the histogram, we finally chose a fixed time <inline-formula><inline-graphic xlink:href="pone.0018204.e086.jpg" mimetype="image"/></inline-formula> for changing from induction- to maintenance therapy. In the sequel, we evaluate, if the chosen time <inline-formula><inline-graphic xlink:href="pone.0018204.e087.jpg" mimetype="image"/></inline-formula> to change from inducer- to maintenance combination leads to a general improvement compared to conventional HAART therapy, in terms of treatment success and drug resistance archiving.</p><fig id="pone-0018204-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0018204.g003</object-id><label>Figure 3</label><caption><title>Histogram of optimal, individual treatment switching times.</title><p>Switching times for changing from inducer- to maintenance therapy were automatically determined and carried out (using eq. (1)). The 0.5th percentile, marked by the red line, was determined and the corresponding time <inline-formula><inline-graphic xlink:href="pone.0018204.e088.jpg" mimetype="image"/></inline-formula> days was used as a fixed value in the suggested strategy to switch from inducer- to maintenance therapy. Hybrid deterministic-stochastic simulations were performed at clinically relevant parameter sets (see <xref ref-type="supplementary-material" rid="pone.0018204.s002">Table S1</xref>). Drug switches occurred in a total of 5478 out of 6000 simulations.</p></caption><graphic xlink:href="pone.0018204.g003"/></fig></sec><sec id="s2c"><title>Determination of treatment changing time</title><p>In <xref rid="pone.0018204-vonKleist1" ref-type="bibr">[23]</xref> we introduced the &#x02018;reproductive capacity&#x02019; <inline-formula><inline-graphic xlink:href="pone.0018204.e089.jpg" mimetype="image"/></inline-formula>. For the extended model used herein, we have provided the derivation of <inline-formula><inline-graphic xlink:href="pone.0018204.e090.jpg" mimetype="image"/></inline-formula> in the <xref ref-type="sec" rid="s4">
<italic>Materials and Methods</italic>
</xref> section. The reproductive capacity <inline-formula><inline-graphic xlink:href="pone.0018204.e091.jpg" mimetype="image"/></inline-formula> can be envisaged as the amount of offspring that the whole viral population is expected to produce under some treatment <inline-formula><inline-graphic xlink:href="pone.0018204.e092.jpg" mimetype="image"/></inline-formula> during one round of replication. It can be calculated from any model simulation and enables to evaluate each state of the infection from the perspective of any potential treatment <inline-formula><inline-graphic xlink:href="pone.0018204.e093.jpg" mimetype="image"/></inline-formula>. As the viral population adapts to some currently applied treatment, <inline-formula><inline-graphic xlink:href="pone.0018204.e094.jpg" mimetype="image"/></inline-formula> changes accordingly: <inline-formula><inline-graphic xlink:href="pone.0018204.e095.jpg" mimetype="image"/></inline-formula> is large initially and decreases subsequently until drug resistant strains develop and render the treatment <inline-formula><inline-graphic xlink:href="pone.0018204.e096.jpg" mimetype="image"/></inline-formula> inefficient. We want to assess the point in time, when some inducer- drug combination stops to provide any benefits (in terms of the viral population) for the <italic>next</italic> drug combination (maintenance combination). We therefore evaluate <inline-formula><inline-graphic xlink:href="pone.0018204.e097.jpg" mimetype="image"/></inline-formula> for <inline-formula><inline-graphic xlink:href="pone.0018204.e098.jpg" mimetype="image"/></inline-formula> while the induction combination is applied and change from the induction- to the maintenance therapy when <inline-formula><inline-graphic xlink:href="pone.0018204.e099.jpg" mimetype="image"/></inline-formula> reaches its minimum;<disp-formula><graphic xlink:href="pone.0018204.e100.jpg" mimetype="image" position="float"/><label>(1)</label></disp-formula>
</p><p>The derived switch-times are displayed in <xref ref-type="fig" rid="pone-0018204-g003">Fig. 3</xref>. We chose the 0.5th percentile at <inline-formula><inline-graphic xlink:href="pone.0018204.e101.jpg" mimetype="image"/></inline-formula> days as a fixed time for treatment change in the forthcoming evaluation of the proposed induction-maintenance-strategy.</p></sec><sec id="s2d"><title>Implementation of conventional vs. proposed induction-maintenance-strategy</title><p>In order to reflect the clinical practice of HIV care, we have implemented the following routine for assessing the efficacy of the applied treatment combinations.</p><p>Our virtual patients are monitored every month for efficacy assessment until virus levels fall below the limit of detection (50 HIV RNA/mL plasma). Thereafter, they are monitored every other month. Virological failure has been defined according to treatment guidelines <xref rid="pone.0018204-Panel1" ref-type="bibr">[24]</xref>: At the first efficacy assessment (one month after treatment initiation), viral load should have fallen by at least 2 logs [HIV RNA/mL plasma]. Each consecutive measurement should be below the previous assessment. By month 4, viral load should be below the level of detection (50 HIV RNA/mL plasma). After that, detectable virus is defined as virological failure.</p><p>We implemented conventional HAART in the following way: The virtual patients are initially treated with a drug combination consisting of two nucleoside reverse transcriptase inhibitors (NRTIs) and one non-nucleoside reverse transcriptase inhibitor (NNRTI) (e.g. tenofovir (TDF) &#x0002b; emtricitabine (FTC) &#x0002b; efavirenz (EFV)), until virological failure is detected, in which case treatment is changed to a second line regimen consisting of a protease inhibitor (PI), an integrase inhibitor (InI) and an entry inhibitor (EI) (e.g. ritonavir (RTV) -boosted PI &#x0002b; raltegravir (RLV) &#x0002b; maraviroc (MVR)).</p><p>In the proposed induction-maintenance-strategy, patients are initially treated with a combination consisting of a PI, an InI and an EI, until <inline-formula><inline-graphic xlink:href="pone.0018204.e102.jpg" mimetype="image"/></inline-formula> days. After that, a treatment consisting of two NRTIs and one NNRTI is applied. If failure is detected at any efficacy assessment time point, treatment change is applied.</p><p>In the following, we performed 1000 hybrid stochastic-deterministic simulations for each relevant parameter set (deduced from <xref ref-type="supplementary-material" rid="pone.0018204.s002">Table S1</xref>) and counted the number of realizations, in which virological failure occurred. Furthermore, we assessed, if the number of drug resistant mutants in the very long-lived infected cells <inline-formula><inline-graphic xlink:href="pone.0018204.e103.jpg" mimetype="image"/></inline-formula> was higher at the end of the simulation than upon initiation of treatment. In this case we recorded &#x0201c;archiving&#x0201d; of drug resistance. The results of our simulations are discussed in the next section.</p></sec><sec id="s2e"><title>Proposed induction-maintenance-strategy improves success rate and minimizes archiving of drug-resistance</title><p>
<xref ref-type="fig" rid="pone-0018204-g004">Fig. 4A</xref> shows that the proposed induction-maintenance-strategy (blue line) with a fixed treatment switch time of <inline-formula><inline-graphic xlink:href="pone.0018204.e104.jpg" mimetype="image"/></inline-formula> days leads to a significant reduction in the probability to experience virological failure compared to the conventional treatment strategy (red line). This observation holds true for a wide range of parameters (see <xref ref-type="table" rid="pone-0018204-t002">Table 2</xref>, second column). In only two cases, where failure rarely occurs during conventional therapy, we do not get significant differences at the p&#x0200a;=&#x0200a;0.05 level.</p><fig id="pone-0018204-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0018204.g004</object-id><label>Figure 4</label><caption><title>Kaplan-Meier estimates for treatment success, and correlation between virological failure and archiving of drug resistance.</title><p>The plots summarize the results trough the whole simulated parameter space from <xref ref-type="table" rid="pone-0018204-t002">Table 2</xref> (12000 simulations in total). A: Probability of no virological failure (&#x00025;) for the IM-strategy (blue line) and the conventional therapy (red line), respectively. Dashed lines are the 95&#x00025; confidence ranges, calculated using Greenwood's formula. Virological failure was defined according to <xref rid="pone.0018204-Panel1" ref-type="bibr">[24]</xref> and is summarized in section &#x0201c;Implementation of conventional vs. proposed induction-maintenance-strategy&#x0201d;. B: The probability to virological failure vs. the average number of drug resistance archiving in the latent reservoir. A strong positive correlation (<inline-formula><inline-graphic xlink:href="pone.0018204.e105.jpg" mimetype="image"/></inline-formula>) between virological failure and drug resistance archiving exists, as indicated by spearman's non-parametric rank correlation coefficient <inline-formula><inline-graphic xlink:href="pone.0018204.e106.jpg" mimetype="image"/></inline-formula>.</p></caption><graphic xlink:href="pone.0018204.g004"/></fig><table-wrap id="pone-0018204-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0018204.t002</object-id><label>Table 2</label><caption><title>Probability of virological failure and -archivation of multi-drug resistant virus during suggested induction-maintenance- (IM) vs. conventional HAART strategy.</title></caption><alternatives><graphic id="pone-0018204-t002-2" xlink:href="pone.0018204.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Parameter set</td><td align="left" rowspan="1" colspan="1">Failure rate</td><td colspan="3" align="left" rowspan="1">Probability of multi-drug resistance archivation</td></tr><tr><td align="left" rowspan="1" colspan="1">ID (<inline-formula><inline-graphic xlink:href="pone.0018204.e107.jpg" mimetype="image"/></inline-formula>)</td><td align="left" rowspan="1" colspan="1">IM, HAART</td><td align="left" rowspan="1" colspan="1">&#x02265;2 mutations</td><td align="left" rowspan="1" colspan="1">&#x02265;3 mutations</td><td align="left" rowspan="1" colspan="1">&#x02265;5 mutations</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">R1 <inline-formula><inline-graphic xlink:href="pone.0018204.e108.jpg" mimetype="image"/></inline-formula>
</td><td align="left" rowspan="1" colspan="1">1.7, 4.8&#x00025;<inline-formula><inline-graphic xlink:href="pone.0018204.e109.jpg" mimetype="image"/></inline-formula>
</td><td align="left" rowspan="1" colspan="1">1.8,4.8&#x00025;<inline-formula><inline-graphic xlink:href="pone.0018204.e110.jpg" mimetype="image"/></inline-formula>
</td><td align="left" rowspan="1" colspan="1">1.7,4.8&#x00025;<inline-formula><inline-graphic xlink:href="pone.0018204.e111.jpg" mimetype="image"/></inline-formula>
</td><td align="left" rowspan="1" colspan="1">0,0.1&#x00025;</td></tr><tr><td align="left" rowspan="1" colspan="1">R2 <inline-formula><inline-graphic xlink:href="pone.0018204.e112.jpg" mimetype="image"/></inline-formula>
</td><td align="left" rowspan="1" colspan="1">4.2, 14.2&#x00025;<inline-formula><inline-graphic xlink:href="pone.0018204.e113.jpg" mimetype="image"/></inline-formula>
</td><td align="left" rowspan="1" colspan="1">4.8,14.2&#x00025;<inline-formula><inline-graphic xlink:href="pone.0018204.e114.jpg" mimetype="image"/></inline-formula>
</td><td align="left" rowspan="1" colspan="1">4.2,13.9&#x00025;<inline-formula><inline-graphic xlink:href="pone.0018204.e115.jpg" mimetype="image"/></inline-formula>
</td><td align="left" rowspan="1" colspan="1">0.1,0.2&#x00025;</td></tr><tr><td align="left" rowspan="1" colspan="1">R3 <inline-formula><inline-graphic xlink:href="pone.0018204.e116.jpg" mimetype="image"/></inline-formula>
</td><td align="left" rowspan="1" colspan="1">6.6, 41.8&#x00025;<inline-formula><inline-graphic xlink:href="pone.0018204.e117.jpg" mimetype="image"/></inline-formula>
</td><td align="left" rowspan="1" colspan="1">18.5,42.2&#x00025;<inline-formula><inline-graphic xlink:href="pone.0018204.e118.jpg" mimetype="image"/></inline-formula>
</td><td align="left" rowspan="1" colspan="1">9.6,41.6&#x00025;<inline-formula><inline-graphic xlink:href="pone.0018204.e119.jpg" mimetype="image"/></inline-formula>
</td><td align="left" rowspan="1" colspan="1">0.1,2.9&#x00025;<inline-formula><inline-graphic xlink:href="pone.0018204.e120.jpg" mimetype="image"/></inline-formula>
</td></tr><tr><td align="left" rowspan="1" colspan="1">R4 <inline-formula><inline-graphic xlink:href="pone.0018204.e121.jpg" mimetype="image"/></inline-formula>
</td><td align="left" rowspan="1" colspan="1">0.9, 2.8&#x00025;<inline-formula><inline-graphic xlink:href="pone.0018204.e122.jpg" mimetype="image"/></inline-formula>
</td><td align="left" rowspan="1" colspan="1">0.9,2.9&#x00025;<inline-formula><inline-graphic xlink:href="pone.0018204.e123.jpg" mimetype="image"/></inline-formula>
</td><td align="left" rowspan="1" colspan="1">0.9,2.8&#x00025;<inline-formula><inline-graphic xlink:href="pone.0018204.e124.jpg" mimetype="image"/></inline-formula>
</td><td align="left" rowspan="1" colspan="1">0,0&#x00025;</td></tr><tr><td align="left" rowspan="1" colspan="1">R5 <inline-formula><inline-graphic xlink:href="pone.0018204.e125.jpg" mimetype="image"/></inline-formula>
</td><td align="left" rowspan="1" colspan="1">1.8, 12.5&#x00025;<inline-formula><inline-graphic xlink:href="pone.0018204.e126.jpg" mimetype="image"/></inline-formula>
</td><td align="left" rowspan="1" colspan="1">2.2,12.6&#x00025;<inline-formula><inline-graphic xlink:href="pone.0018204.e127.jpg" mimetype="image"/></inline-formula>
</td><td align="left" rowspan="1" colspan="1">1.8,12.5&#x00025;<inline-formula><inline-graphic xlink:href="pone.0018204.e128.jpg" mimetype="image"/></inline-formula>
</td><td align="left" rowspan="1" colspan="1">0,0.4&#x00025;</td></tr><tr><td align="left" rowspan="1" colspan="1">R6 <inline-formula><inline-graphic xlink:href="pone.0018204.e129.jpg" mimetype="image"/></inline-formula>
</td><td align="left" rowspan="1" colspan="1">0.7, 2.2&#x00025;<inline-formula><inline-graphic xlink:href="pone.0018204.e130.jpg" mimetype="image"/></inline-formula>
</td><td align="left" rowspan="1" colspan="1">0.8,2.3&#x00025;<inline-formula><inline-graphic xlink:href="pone.0018204.e131.jpg" mimetype="image"/></inline-formula>
</td><td align="left" rowspan="1" colspan="1">0.7,2.2&#x00025;<inline-formula><inline-graphic xlink:href="pone.0018204.e132.jpg" mimetype="image"/></inline-formula>
</td><td align="left" rowspan="1" colspan="1">0,0.2&#x00025;</td></tr><tr><td align="left" rowspan="1" colspan="1">R7 <inline-formula><inline-graphic xlink:href="pone.0018204.e133.jpg" mimetype="image"/></inline-formula>
</td><td align="left" rowspan="1" colspan="1">3.1, 21.9&#x00025; <inline-formula><inline-graphic xlink:href="pone.0018204.e134.jpg" mimetype="image"/></inline-formula>
</td><td align="left" rowspan="1" colspan="1">2.8,22.1&#x00025; <inline-formula><inline-graphic xlink:href="pone.0018204.e135.jpg" mimetype="image"/></inline-formula>
</td><td align="left" rowspan="1" colspan="1">3.1,21.9&#x00025; <inline-formula><inline-graphic xlink:href="pone.0018204.e136.jpg" mimetype="image"/></inline-formula>
</td><td align="left" rowspan="1" colspan="1">0.2,0.9&#x00025; <inline-formula><inline-graphic xlink:href="pone.0018204.e137.jpg" mimetype="image"/></inline-formula>
</td></tr><tr><td align="left" rowspan="1" colspan="1">R8 <inline-formula><inline-graphic xlink:href="pone.0018204.e138.jpg" mimetype="image"/></inline-formula>
</td><td align="left" rowspan="1" colspan="1">7.9, 44&#x00025; <inline-formula><inline-graphic xlink:href="pone.0018204.e139.jpg" mimetype="image"/></inline-formula>
</td><td align="left" rowspan="1" colspan="1">9.3,44&#x00025; <inline-formula><inline-graphic xlink:href="pone.0018204.e140.jpg" mimetype="image"/></inline-formula>
</td><td align="left" rowspan="1" colspan="1">8.3,44&#x00025; <inline-formula><inline-graphic xlink:href="pone.0018204.e141.jpg" mimetype="image"/></inline-formula>
</td><td align="left" rowspan="1" colspan="1">0.7,14.6&#x00025; <inline-formula><inline-graphic xlink:href="pone.0018204.e142.jpg" mimetype="image"/></inline-formula>
</td></tr><tr><td align="left" rowspan="1" colspan="1">R9 <inline-formula><inline-graphic xlink:href="pone.0018204.e143.jpg" mimetype="image"/></inline-formula>
</td><td align="left" rowspan="1" colspan="1">0.6, 0.6&#x00025;</td><td align="left" rowspan="1" colspan="1">0.9,1.3&#x00025;</td><td align="left" rowspan="1" colspan="1">0.6,0.6&#x00025;</td><td align="left" rowspan="1" colspan="1">0,0&#x00025;</td></tr><tr><td align="left" rowspan="1" colspan="1">R10 <inline-formula><inline-graphic xlink:href="pone.0018204.e144.jpg" mimetype="image"/></inline-formula>
</td><td align="left" rowspan="1" colspan="1">2.4,7.1&#x00025; <inline-formula><inline-graphic xlink:href="pone.0018204.e145.jpg" mimetype="image"/></inline-formula>
</td><td align="left" rowspan="1" colspan="1">2.7,8.1&#x00025; <inline-formula><inline-graphic xlink:href="pone.0018204.e146.jpg" mimetype="image"/></inline-formula>
</td><td align="left" rowspan="1" colspan="1">2.4,7.2&#x00025; <inline-formula><inline-graphic xlink:href="pone.0018204.e147.jpg" mimetype="image"/></inline-formula>
</td><td align="left" rowspan="1" colspan="1">0.3,0.4&#x00025;</td></tr><tr><td align="left" rowspan="1" colspan="1">R11 <inline-formula><inline-graphic xlink:href="pone.0018204.e148.jpg" mimetype="image"/></inline-formula>
</td><td align="left" rowspan="1" colspan="1">33.7, 59.1&#x00025; <inline-formula><inline-graphic xlink:href="pone.0018204.e149.jpg" mimetype="image"/></inline-formula>
</td><td align="left" rowspan="1" colspan="1">34.7,59.5&#x00025; <inline-formula><inline-graphic xlink:href="pone.0018204.e150.jpg" mimetype="image"/></inline-formula>
</td><td align="left" rowspan="1" colspan="1">34,59.3&#x00025; <inline-formula><inline-graphic xlink:href="pone.0018204.e151.jpg" mimetype="image"/></inline-formula>
</td><td align="left" rowspan="1" colspan="1">3.4,17.2&#x00025; <inline-formula><inline-graphic xlink:href="pone.0018204.e152.jpg" mimetype="image"/></inline-formula>
</td></tr><tr><td align="left" rowspan="1" colspan="1">R12 <inline-formula><inline-graphic xlink:href="pone.0018204.e153.jpg" mimetype="image"/></inline-formula>
</td><td align="left" rowspan="1" colspan="1">1.2, 1.8&#x00025;</td><td align="left" rowspan="1" colspan="1">2.3,2.5&#x00025;</td><td align="left" rowspan="1" colspan="1">1.3,1.8&#x00025;</td><td align="left" rowspan="1" colspan="1">0.1,0.1&#x00025;</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt102"><label/><p>Columns 2&#x02013;5 show the distinct treatment outcome for the suggested induction-maintenance strategy (left entry) and a conventional HAART strategy (right entry) for different parameter sets R1&#x02013;R12 in terms of mutation-associated reproductive fitness losses <inline-formula><inline-graphic xlink:href="pone.0018204.e154.jpg" mimetype="image"/></inline-formula> and different levels of drug efficacy <inline-formula><inline-graphic xlink:href="pone.0018204.e155.jpg" mimetype="image"/></inline-formula> (indicated in column 1), following 1000 simulations respectively. Relevant parameter combinations had been identified beforehand, see <xref ref-type="supplementary-material" rid="pone.0018204.s002">Table S1</xref> and section &#x0201c;Treatment change before virological failure&#x0201d;. Column 2: Percentage of virological failure after 2 years of therapy according to the HIV treatment guidelines (summarized in section &#x0201c;Implementation of conventional vs. suggested induction-maintenance strategy&#x0201d;). Column 3&#x02013;5: Probability of multi-drug resistance archiving during the proposed strategy and during conventional HAART strategy. Cross tab <inline-formula><inline-graphic xlink:href="pone.0018204.e156.jpg" mimetype="image"/></inline-formula> tests of independence between treatment strategy (suggested vs. conventional strategy) and outcome (virological failure or archivation of multi-drug resistance) are stated. A small <inline-formula><inline-graphic xlink:href="pone.0018204.e157.jpg" mimetype="image"/></inline-formula>-value indicates that the distinct outcome depends on the treatment strategy and is not due to random effects (&#x0002a;&#x0002a; <inline-formula><inline-graphic xlink:href="pone.0018204.e158.jpg" mimetype="image"/></inline-formula>, &#x0002a; <inline-formula><inline-graphic xlink:href="pone.0018204.e159.jpg" mimetype="image"/></inline-formula>).</p></fn></table-wrap-foot></table-wrap><p>
<xref ref-type="fig" rid="pone-0018204-g004">Fig. 4B</xref> shows that virological failure and the average number of archived drug resistance mutations are strongly correlated (spearman's correlation coefficient <inline-formula><inline-graphic xlink:href="pone.0018204.e160.jpg" mimetype="image"/></inline-formula>, <inline-formula><inline-graphic xlink:href="pone.0018204.e161.jpg" mimetype="image"/></inline-formula>). This indicates that virological failure is a strong predictor for drug resistance archiving.</p><p>
<xref ref-type="table" rid="pone-0018204-t002">Tables 2</xref> (third&#x02013;fifth column) show the number of cases in which archiving of multi-drug resistant viral strains (with <inline-formula><inline-graphic xlink:href="pone.0018204.e162.jpg" mimetype="image"/></inline-formula>, <inline-formula><inline-graphic xlink:href="pone.0018204.e163.jpg" mimetype="image"/></inline-formula> and <inline-formula><inline-graphic xlink:href="pone.0018204.e164.jpg" mimetype="image"/></inline-formula> drug resistance mutations) occurred in the latent reservoir, under the proposed induction-maintenance strategy and conventional HAART, respectively. It can be seen that the proposed treatment strategy leads to a significant reduction in multi-drug resistance archiving for the majority of parameters evaluated. This indicates, that although two treatment lines have been used for the novel therapy, more therapeutic options are on average available in the follow-up period, compared to conventional therapy.</p></sec></sec><sec id="s3"><title>Discussion</title><p>We have presented and tested (in terms of a mathematical model) a very simple treatment strategy that can lead to significant reductions in virological failure in comparison to conventional HAART treatment. A unique drug combination (inducer combination) is used for a short time (80 days) and pro-actively switched to a maintenance combination. The purpose of the inducer combination is to decrease viral population size and thereby increase the likelihood that the subsequent therapy (maintenance) will achieve durable suppression. Clinical implementation of this novel treatment strategy requires only one additional clinical visit at 80 days in comparison with the conventional HAART therapy. The important finding of our study is, that although two drug combinations are always utilized during the proposed induction-maintenance strategy, less archiving of drug resistance occurs in comparison with a conventional treatment strategy, where a second treatment line would be applied only in the case of virological failure or toxicity. Less drug resistance archiving implies that more treatment options will be available for the follow-up and long-term management of HIV-infected patients when the proposed induction-maintenance treatment strategy is used (see <xref ref-type="table" rid="pone-0018204-t002">Table 2</xref>, third&#x02013;fifth column).</p><p>
<xref ref-type="supplementary-material" rid="pone.0018204.s001">Fig. S1</xref> shows that only a few archiving events (<inline-formula><inline-graphic xlink:href="pone.0018204.e165.jpg" mimetype="image"/></inline-formula> fully resistant mutants) are sufficient to eliminate treatment options permanently. The number of circulating latently infected cells is small <xref rid="pone.0018204-Finzi2" ref-type="bibr">[2]</xref>, <xref rid="pone.0018204-Chun3" ref-type="bibr">[7]</xref>, <xref rid="pone.0018204-Blankson1" ref-type="bibr">[30]</xref>, <xref rid="pone.0018204-Fondere1" ref-type="bibr">[31]</xref>. Detecting a small subset of mutants within the circulating latently infected cells is experimentally not feasible, because standard sequencing technology will detect the major strains <xref rid="pone.0018204-Richman1" ref-type="bibr">[32]</xref>, while novel, second generation methods require large samples <xref rid="pone.0018204-Eriksson1" ref-type="bibr">[33]</xref>. Hence, mathematical modelling is a reasonable tool to investigate drug resistance archiving following treatment application.</p><p>The time for switching between combinations <inline-formula><inline-graphic xlink:href="pone.0018204.e166.jpg" mimetype="image"/></inline-formula> (&#x0200a;=&#x0200a;80 days) is the most critical parameter for the success of the proposed strategy. The following two considerations have to be taken into account: (i) The inducer combination should be applied only for a short time, to prevent the selection and archiving of mutants, which are resistant to the <italic>current</italic> drug combination and would limit the further use of this drug combination (risk of the strategy), (ii) while at the same time, it has to be applied long enough to possibly eradicate viral mutants, which are resistant to the <italic>next</italic> drug combination (the benefit of the strategy).</p><p>The time required for resistant mutants to emerge, depends on their abundance before the initiation of therapy (if they pre-exist and are selected from the population) and also on their genetic distance to the wildtype (if resistance is <italic>de novo</italic> developed). As discussed above, we determine the abundance of mutants at the time of therapy initiation by utilizing the deterministic fix-point as starting condition for our simulations. We have shown the non-inferiority of our approach in <xref ref-type="fig" rid="pone-0018204-g005">Fig. 5</xref>, if drug resistant mutants are more abundant than expected. We have assumed the shortest genetic distance possible between wildtype and fully drug resistant mutants (one mutation is sufficient to create full resistance against a single drug, three distinct mutations are required for full resistance against a triple-drug combination). For some drugs, however, subsequent accumulation of mutations creates fully drug resistant mutants <xref rid="pone.0018204-Nijhuis1" ref-type="bibr">[34]</xref>. In our model, drug resistance might therefore develop more rapidly than <italic>in vivo</italic> for drugs with a large genetic barrier <xref rid="pone.0018204-Arora1" ref-type="bibr">[35]</xref>. This implies that <italic>in vivo</italic> the inducer combination could possibly be applied for a longer time frame than the 80 days utilized in our model, if the genetic distance between wildtype and fully drug resistant mutant was greater than considered here (greater than one point mutation). However, our results demonstrate that even a very short time (80 days) in which the inducer combination is applied, can improve the clinical outcome significantly (see <xref ref-type="fig" rid="pone-0018204-g004">Fig. 4</xref> and <xref ref-type="table" rid="pone-0018204-t002">Table 2</xref>). This short time already minimizes the probability that drug resistance emerges and can, in that sense, be considered safer than a longer induction phase.</p><fig id="pone-0018204-g005" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0018204.g005</object-id><label>Figure 5</label><caption><title>Kaplan-Meier estimates of treatment success (probability of no virological failure) for very high initial abundance of drug resistant mutants.</title><p>The figure shows the outcome of 500 simulations for the proposed induction-maintenance strategy (blue line) and for the conventional HAART therapy (red line), respectively. Dashed lines indicate the 95&#x00025; confidence ranges, calculated using Greenwood's formula. The initial abundance of drug resistant mutants was set to 1&#x00025; of the population. Other parameter values: <inline-formula><inline-graphic xlink:href="pone.0018204.e167.jpg" mimetype="image"/></inline-formula>&#x0200a;=&#x0200a;0.75, <inline-formula><inline-graphic xlink:href="pone.0018204.e168.jpg" mimetype="image"/></inline-formula>&#x0200a;=&#x0200a;0.8.</p></caption><graphic xlink:href="pone.0018204.g005"/></fig><p>Eradication of viral mutants depends critically on their abundance prior to the initiation of therapy and on the rate at which viral compartments (and therefore resistant mutants) are cleared <italic>in vivo</italic>. The elimination of viral compartments <italic>in vivo</italic> has been quantified and validated in a number of clinical studies <xref rid="pone.0018204-Markowitz1" ref-type="bibr">[36]</xref>&#x02013;<xref rid="pone.0018204-Perelson2" ref-type="bibr">[38]</xref>. We used the expected abundance of viral mutants (the deterministic fix-point of the model) to estimate the abundance of different viral mutants at the time of treatment initiation. In <xref ref-type="fig" rid="pone-0018204-g005">Fig. 5</xref> we show non-inferiority of our approach in the case, where an unexpectedly high abundance of drug resistant mutants is present (1&#x00025; of the wildtype; detection limit of second generation sequencing technologies <xref rid="pone.0018204-Eriksson1" ref-type="bibr">[33]</xref>, <xref rid="pone.0018204-Ji1" ref-type="bibr">[39]</xref>, <xref rid="pone.0018204-Archer1" ref-type="bibr">[40]</xref>), which would require longer time for eradication.</p><p>One limitation of the proposed induction-maintenance strategy is the potential inability to eliminate viral strains, that carry resistance to the maintenance therapy. This is particularly the case, if viral mutants, which carry resistance against all (or at least the majority of) drugs in the maintenance combination, are archived in the latent reservoir prior to treatment initiation. In <xref ref-type="supplementary-material" rid="pone.0018204.s001">Fig. S1B</xref>, we have quantified that <inline-formula><inline-graphic xlink:href="pone.0018204.e169.jpg" mimetype="image"/></inline-formula> 40 fully resistant viral mutants in the latent reservoir eliminate treatment options permanently. However, the likelihood for fully resistant archival copies (resistant against all drugs in the maintenance regimen) in the treatment naive patient, who was infected with wildtype <inline-formula><inline-graphic xlink:href="pone.0018204.e170.jpg" mimetype="image"/></inline-formula> virus, is relatively small. Based on quasi-species theory, Ribero et al. <xref rid="pone.0018204-Ribeiro1" ref-type="bibr">[41]</xref> calculated the pre-treatment frequency of viral mutants. According to <xref rid="pone.0018204-Ribeiro1" ref-type="bibr">[41]</xref>, the frequency of double mutants (part-resistant) relative to the wildtype equals<disp-formula><graphic xlink:href="pone.0018204.e171.jpg" mimetype="image" position="float"/><label>(2)</label></disp-formula>where <inline-formula><inline-graphic xlink:href="pone.0018204.e172.jpg" mimetype="image"/></inline-formula> and <inline-formula><inline-graphic xlink:href="pone.0018204.e173.jpg" mimetype="image"/></inline-formula> are the selective disadvantages of the strain carrying the first-, the second- and the both drug-resistance mutations and <inline-formula><inline-graphic xlink:href="pone.0018204.e174.jpg" mimetype="image"/></inline-formula> is the single point mutation rate <xref rid="pone.0018204-Mansky1" ref-type="bibr">[42]</xref>. It is reasonable to assume that resistant mutants are, at best, as likely to enter the latent reservoir as the wildtype in the absence of any drugs, due to their inherent fitness loss, i.e. <inline-formula><inline-graphic xlink:href="pone.0018204.e175.jpg" mimetype="image"/></inline-formula>. Considering a maintenance combination consisting of efavirenz (EFV), tenofovir (TDF) and emtricitabine (FTC), with primary resistance mutations K103N, K65R and M184V and respective selective disadvantages for the single-point mutants <inline-formula><inline-graphic xlink:href="pone.0018204.e176.jpg" mimetype="image"/></inline-formula> and <inline-formula><inline-graphic xlink:href="pone.0018204.e177.jpg" mimetype="image"/></inline-formula>
<xref rid="pone.0018204-MartinezPicado2" ref-type="bibr">[43]</xref> and additive fitness losses in the double mutants <inline-formula><inline-graphic xlink:href="pone.0018204.e178.jpg" mimetype="image"/></inline-formula> (i.e. <inline-formula><inline-graphic xlink:href="pone.0018204.e179.jpg" mimetype="image"/></inline-formula>), the probability that mutants, resistant against two out of three maintenance drugs, enter the latent reservoir are <inline-formula><inline-graphic xlink:href="pone.0018204.e180.jpg" mimetype="image"/></inline-formula> and <inline-formula><inline-graphic xlink:href="pone.0018204.e181.jpg" mimetype="image"/></inline-formula> respectively. Using <italic>in vivo</italic> data, Chun et al. <xref rid="pone.0018204-Chun3" ref-type="bibr">[7]</xref> estimated the average number of latently infected cells with replication-competent provirus to be <inline-formula><inline-graphic xlink:href="pone.0018204.e182.jpg" mimetype="image"/></inline-formula> cells, so that the expected number of partly-resistant mutants <inline-formula><inline-graphic xlink:href="pone.0018204.e183.jpg" mimetype="image"/></inline-formula> that are archived prior to treatment initiation is <inline-formula><inline-graphic xlink:href="pone.0018204.e184.jpg" mimetype="image"/></inline-formula> and <inline-formula><inline-graphic xlink:href="pone.0018204.e185.jpg" mimetype="image"/></inline-formula>. In other words, it is very unlikely that part-resistant mutants are archived in patients prior to treatment, since <inline-formula><inline-graphic xlink:href="pone.0018204.e186.jpg" mimetype="image"/></inline-formula>. Furthermore, part-resistant mutants are still susceptible to one out of the three drugs in the maintenance combination. For triple-drug (fully) resistant strains, the likelihood of archival copies is even smaller.</p><p>Infection with drug resistant strains, mainly against established drug classes, is a major, growing health concern <xref rid="pone.0018204-Smith1" ref-type="bibr">[44]</xref>. During infection with drug-resistant viral strains, archivation in the latent reservoir is likely, since this reservoir is established early in the infection <xref rid="pone.0018204-Ghosn1" ref-type="bibr">[45]</xref>. If the circulating viral population reverses to a drug-susceptible type, archived resistant mutants from the time of infection might remain undetected and can complicate subsequent treatment (see <xref ref-type="supplementary-material" rid="pone.0018204.s001">Fig. S1</xref>). This particular circumstance applies equally to the proposed induction-maintenance therapy and conventional HAART.</p><p>For our strategy, we have chosen drugs from novel classes (e.g. InI, EI) for the inducer-combination, while we selected drugs from well-established classes for the maintenance combination (NNRTI, NRTI). This has the following rationale: The inducer combination will only be applied for a short time (80 days), while the maintenance combination could possibly be applied for much longer periods of time (until it fails, or toxicological events occur). Second or third generation drugs within the established drug-classes are often more convenient to apply (e.g. once daily dosing) and are less toxic, which has important implications for the long-term management of HIV <xref rid="pone.0018204-Bartlett1" ref-type="bibr">[46]</xref>. Secondly, drugs from the novel drug classes (InI, EI), are currently not available as generic formulations, whereas low-cost alternative drugs exist for established drug classes. Therefore, in order to reduce treatment costs, it is of advantage to select a strategy, in which inexpensive drugs can be used for the majority of time, while cost-intensive ones are only applied for short treatment periods.</p><p>Some drug classes can cause a distinct viral load decline. In particular, the only approved InI raltegravir causes a more rapid viral load decay, compared with other HIV inhibitors <xref rid="pone.0018204-Murray1" ref-type="bibr">[47]</xref>, <xref rid="pone.0018204-DeJesus1" ref-type="bibr">[48]</xref>. It might therefore seem logical, based on viral load decay, to use raltegravir in the induction treatment. It has been shown, however, that the faster viral decay with raltegravir could be a consequence of the particular site of action of InIs within the viral life cycle and may not be due to an overall increased removal rate of replication-competent viral compartments by raltegravir <xref rid="pone.0018204-vonKleist1" ref-type="bibr">[23]</xref>, <xref rid="pone.0018204-Sedaghat1" ref-type="bibr">[49]</xref>. Long-term studies of raltegravir- versus efavirenz-based HAART showed equal outcomes with either therapies <xref rid="pone.0018204-Lennox1" ref-type="bibr">[50]</xref>, <xref rid="pone.0018204-Lennox2" ref-type="bibr">[51]</xref>, arguing against the superiority of raltegravir-based drug combinations in removing replication-competent virus; however, further analysis is required.</p><p>Intuitively, it might be more advantageous to use drug resistance tests to guide treatment switches, instead of using a fixed time for a pro-active switch from inducer- to maintenance combination <xref rid="pone.0018204-DAmato1" ref-type="bibr">[19]</xref>. However, under the considerations discussed above, a switch from inducer- to maintenance combination should be applied before any resistant strains become abundant. This implies that the most frequent viral strain at the time of switch should be the wildtype. Standard assays fail to detect minority species <xref rid="pone.0018204-Richman1" ref-type="bibr">[32]</xref>. Ultra-deep/pyro-sequencing might provide a more holistic picture of the quasi-species composition and can pick up viral mutants that are abundant in <inline-formula><inline-graphic xlink:href="pone.0018204.e187.jpg" mimetype="image"/></inline-formula> of the quasi-species population and if the sample is large enough <xref rid="pone.0018204-Eriksson1" ref-type="bibr">[33]</xref>, <xref rid="pone.0018204-Ji1" ref-type="bibr">[39]</xref>, <xref rid="pone.0018204-Archer1" ref-type="bibr">[40]</xref>. However, even in this case, viral mutants are likely to dominate once the results are available (<inline-formula><inline-graphic xlink:href="pone.0018204.e188.jpg" mimetype="image"/></inline-formula> week), owing to the rapid viral kinetics <xref rid="pone.0018204-Ramratnam1" ref-type="bibr">[52]</xref>.</p><p>In our <italic>in silico</italic> study, we considered time-invariant, as well as anatomically homogeneous <italic>average</italic> drug efficacy <inline-formula><inline-graphic xlink:href="pone.0018204.e189.jpg" mimetype="image"/></inline-formula>, for the ease of modelling. It is also possible to consider drug- and patient-specific time-varying pharmacokinetics and to study the impact of compliance on drug resistance development. However, if compliance is identical between the two study arms, the qualitative difference between the outcome of conventional HAART versus the proposed induction-maintenance strategy is not expected to change. As shown in <xref ref-type="table" rid="pone-0018204-t002">Table 2</xref>, the proposed induction-maintenance therapy performs better than conventional HAART for a wide range of parameter values for <inline-formula><inline-graphic xlink:href="pone.0018204.e190.jpg" mimetype="image"/></inline-formula>. Furthermore, it was shown in a clinical study <xref rid="pone.0018204-MartinezPicado1" ref-type="bibr">[20]</xref>, <xref rid="pone.0018204-Negredo1" ref-type="bibr">[21]</xref> that treatment alternation leads to significantly less virological failure than conventional HAART, when compliance is imperfect but identical between the two study arms. However, since the study in <xref rid="pone.0018204-MartinezPicado1" ref-type="bibr">[20]</xref>, <xref rid="pone.0018204-Negredo1" ref-type="bibr">[21]</xref> is not identical to the treatment strategy presented herein, a clinical study should be performed to fully investigate the potential of the proposed induction-maintenance strategy. Ideally, this prospective randomized trial could evaluate the time to virological failure in patients taking a single unchanged regimen and patients on induction-maintenance regimens. Importantly, the trial should be designed to evaluate whether the induction maintenance strategy affects the durability of second- and third line regimens. The presence and relative frequency of viral minority populations as well as their mutational patterns could be monitored by analyzing proviral DNA from circulating T-cells using, e.g., next-generation sequencing. This data could serve to validate our mathematical model.</p><p>Based on a recent, successful pre-exposure prophylaxis (PrEP) trial, where emtricitabine (FTC) &#x0002b; tenofovir (TDF) were given to high-risk individuals <xref rid="pone.0018204-Grant1" ref-type="bibr">[53]</xref>, it could be envisioned that PrEP is used more broadly. One risk with such a strategy is the selection of FTC/TDF resistance, which occurred in both subjects with acute HIV infection at enrolment in the PrEP trial <xref rid="pone.0018204-Grant1" ref-type="bibr">[53]</xref>. Furthermore, there is a high risk for the selection of drug resistance, if subjects get infected despite PrEP (e.g. due to low adherence; <inline-formula><inline-graphic xlink:href="pone.0018204.e191.jpg" mimetype="image"/></inline-formula> in the PrEP trial <xref rid="pone.0018204-Grant1" ref-type="bibr">[53]</xref>). While FTC/TDF is a core component of first-line HAART, the long-term epidemiological consequences of drug-resistance selection are of utmost importance. One interesting question is whether the proposed induction-maintenance therapy can re-sensitize those subjects towards FTC/TDF treatment, who had become infected with HIV despite PrEP. While a thorough analysis of this question is beyond the scope of the current article, related scenarios are frequently encountered in the context of prevention of mother-to-child transmission (MTCT) programs, when short-course intrapartum nevirapine is used. In the MTCT context, protease-inhibitor-based induction therapy has been used for the re-sensitization of pre-exposed children towards nevirapine <xref rid="pone.0018204-Coovadia1" ref-type="bibr">[54]</xref>. Further analysis, however, is required to elucidate the potential of induction-maintenance strategies for re-sensitization of pre-exposed HIV infected individuals.</p></sec><sec sec-type="materials|methods" id="s4"><title>Materials and Methods</title><sec id="s4a"><title>Model Equations</title><p>The virus dynamics model (<xref ref-type="fig" rid="pone-0018204-g001">Fig. 1</xref>) comprises T-cells, macrophages, free non-infectious virus (<inline-formula><inline-graphic xlink:href="pone.0018204.e192.jpg" mimetype="image"/></inline-formula>, respectively), free infectious virus of mutant strain <inline-formula><inline-graphic xlink:href="pone.0018204.e193.jpg" mimetype="image"/></inline-formula>, and five types of infected cells belonging to mutant strain <inline-formula><inline-graphic xlink:href="pone.0018204.e194.jpg" mimetype="image"/></inline-formula>: infected T-cells and macrophages <italic>prior</italic> to proviral genomic integration (<inline-formula><inline-graphic xlink:href="pone.0018204.e195.jpg" mimetype="image"/></inline-formula> and <inline-formula><inline-graphic xlink:href="pone.0018204.e196.jpg" mimetype="image"/></inline-formula>, respectively) and infected T-cells and macrophages <italic>after</italic> proviral genomic integration (<inline-formula><inline-graphic xlink:href="pone.0018204.e197.jpg" mimetype="image"/></inline-formula> and <inline-formula><inline-graphic xlink:href="pone.0018204.e198.jpg" mimetype="image"/></inline-formula>, respectively). The latently infected cell type <inline-formula><inline-graphic xlink:href="pone.0018204.e199.jpg" mimetype="image"/></inline-formula> does not express viral genes, but can become activated with rate <inline-formula><inline-graphic xlink:href="pone.0018204.e200.jpg" mimetype="image"/></inline-formula>, transforming this cell into a virus producing post-integration infected T-cell <inline-formula><inline-graphic xlink:href="pone.0018204.e201.jpg" mimetype="image"/></inline-formula>. The average rates of change of the different species are given by the following system of ODEs:<disp-formula><graphic xlink:href="pone.0018204.e202.jpg" mimetype="image" position="float"/></disp-formula>
<disp-formula><graphic xlink:href="pone.0018204.e203.jpg" mimetype="image" position="float"/></disp-formula>
<disp-formula><graphic xlink:href="pone.0018204.e204.jpg" mimetype="image" position="float"/></disp-formula>
<disp-formula><graphic xlink:href="pone.0018204.e205.jpg" mimetype="image" position="float"/><label>(3)</label></disp-formula>
<disp-formula><graphic xlink:href="pone.0018204.e206.jpg" mimetype="image" position="float"/></disp-formula>
<disp-formula><graphic xlink:href="pone.0018204.e207.jpg" mimetype="image" position="float"/></disp-formula>
<disp-formula><graphic xlink:href="pone.0018204.e208.jpg" mimetype="image" position="float"/></disp-formula>
<disp-formula><graphic xlink:href="pone.0018204.e209.jpg" mimetype="image" position="float"/></disp-formula>
<disp-formula><graphic xlink:href="pone.0018204.e210.jpg" mimetype="image" position="float"/></disp-formula>where <inline-formula><inline-graphic xlink:href="pone.0018204.e211.jpg" mimetype="image"/></inline-formula> and <inline-formula><inline-graphic xlink:href="pone.0018204.e212.jpg" mimetype="image"/></inline-formula> are the birth rates of uninfected T-cells and macrophages, and <inline-formula><inline-graphic xlink:href="pone.0018204.e213.jpg" mimetype="image"/></inline-formula> and <inline-formula><inline-graphic xlink:href="pone.0018204.e214.jpg" mimetype="image"/></inline-formula> denote their death rate constants. The parameters <inline-formula><inline-graphic xlink:href="pone.0018204.e215.jpg" mimetype="image"/></inline-formula> and <inline-formula><inline-graphic xlink:href="pone.0018204.e216.jpg" mimetype="image"/></inline-formula> are the integration rate constants of mutant strain <inline-formula><inline-graphic xlink:href="pone.0018204.e217.jpg" mimetype="image"/></inline-formula> under treatment <inline-formula><inline-graphic xlink:href="pone.0018204.e218.jpg" mimetype="image"/></inline-formula>. The parameters <inline-formula><inline-graphic xlink:href="pone.0018204.e219.jpg" mimetype="image"/></inline-formula> and <inline-formula><inline-graphic xlink:href="pone.0018204.e220.jpg" mimetype="image"/></inline-formula> are the death rate constants of <inline-formula><inline-graphic xlink:href="pone.0018204.e221.jpg" mimetype="image"/></inline-formula> and <inline-formula><inline-graphic xlink:href="pone.0018204.e222.jpg" mimetype="image"/></inline-formula> cells, respectively. The free virus (infectious and non-infectious) gets cleared by the immune system with rate constant <inline-formula><inline-graphic xlink:href="pone.0018204.e223.jpg" mimetype="image"/></inline-formula>. The parameters <inline-formula><inline-graphic xlink:href="pone.0018204.e224.jpg" mimetype="image"/></inline-formula> and <inline-formula><inline-graphic xlink:href="pone.0018204.e225.jpg" mimetype="image"/></inline-formula> refer to the intracellular degradation of essential components of the pre-integration complex, e.g., by the host cell proteasome within early infected T-cells and macrophages, respectively. <inline-formula><inline-graphic xlink:href="pone.0018204.e226.jpg" mimetype="image"/></inline-formula> and <inline-formula><inline-graphic xlink:href="pone.0018204.e227.jpg" mimetype="image"/></inline-formula> denote the total number of released infectious and non-infectious virus from late infected T-cells and macrophages of mutant strain <inline-formula><inline-graphic xlink:href="pone.0018204.e228.jpg" mimetype="image"/></inline-formula>, and <inline-formula><inline-graphic xlink:href="pone.0018204.e229.jpg" mimetype="image"/></inline-formula> and <inline-formula><inline-graphic xlink:href="pone.0018204.e230.jpg" mimetype="image"/></inline-formula> are the rates of release of infective virus under treatment <inline-formula><inline-graphic xlink:href="pone.0018204.e231.jpg" mimetype="image"/></inline-formula>. The parameters <inline-formula><inline-graphic xlink:href="pone.0018204.e232.jpg" mimetype="image"/></inline-formula> and <inline-formula><inline-graphic xlink:href="pone.0018204.e233.jpg" mimetype="image"/></inline-formula> denote the clearance of mutant virus <inline-formula><inline-graphic xlink:href="pone.0018204.e234.jpg" mimetype="image"/></inline-formula> through unsuccessful infection of T-cells and macrophages, respectively <xref rid="pone.0018204-vonKleist1" ref-type="bibr">[23]</xref>, and the parameters <inline-formula><inline-graphic xlink:href="pone.0018204.e235.jpg" mimetype="image"/></inline-formula> and <inline-formula><inline-graphic xlink:href="pone.0018204.e236.jpg" mimetype="image"/></inline-formula> denote the successful infection rate constants of mutant virus <inline-formula><inline-graphic xlink:href="pone.0018204.e237.jpg" mimetype="image"/></inline-formula> under treatment <inline-formula><inline-graphic xlink:href="pone.0018204.e238.jpg" mimetype="image"/></inline-formula> for T-cells and macrophages, respectively. In our model, T-cells can become latently infected <inline-formula><inline-graphic xlink:href="pone.0018204.e239.jpg" mimetype="image"/></inline-formula> with probability <inline-formula><inline-graphic xlink:href="pone.0018204.e240.jpg" mimetype="image"/></inline-formula>. Latent infected cells can undergo apoptosis with rate <inline-formula><inline-graphic xlink:href="pone.0018204.e241.jpg" mimetype="image"/></inline-formula> and can become activated with rate <inline-formula><inline-graphic xlink:href="pone.0018204.e242.jpg" mimetype="image"/></inline-formula>. Activation of latent cells by antigen- or other activating stimuli triggers the production of viral building blocks via positive feedback loops <xref rid="pone.0018204-Weinberger1" ref-type="bibr">[55]</xref>, <xref rid="pone.0018204-Lassen1" ref-type="bibr">[56]</xref> in the late replication cycle of HIV, which turns the cell into a virus producing cell <inline-formula><inline-graphic xlink:href="pone.0018204.e243.jpg" mimetype="image"/></inline-formula> that becomes susceptible to HIV-related cytopathic effects and destruction by the immune system.</p><p>The parameter <inline-formula><inline-graphic xlink:href="pone.0018204.e244.jpg" mimetype="image"/></inline-formula> denotes the probability to mutate from strain <inline-formula><inline-graphic xlink:href="pone.0018204.e245.jpg" mimetype="image"/></inline-formula> to strain <inline-formula><inline-graphic xlink:href="pone.0018204.e246.jpg" mimetype="image"/></inline-formula> and is defined by<disp-formula><graphic xlink:href="pone.0018204.e247.jpg" mimetype="image" position="float"/><label>(4)</label></disp-formula>where <inline-formula><inline-graphic xlink:href="pone.0018204.e248.jpg" mimetype="image"/></inline-formula> denotes the point mutation probability per base and reverse transcription process (<inline-formula><inline-graphic xlink:href="pone.0018204.e249.jpg" mimetype="image"/></inline-formula>
<xref rid="pone.0018204-Mansky1" ref-type="bibr">[42]</xref>), <inline-formula><inline-graphic xlink:href="pone.0018204.e250.jpg" mimetype="image"/></inline-formula> denotes the hamming distance between strain <inline-formula><inline-graphic xlink:href="pone.0018204.e251.jpg" mimetype="image"/></inline-formula> and strain <inline-formula><inline-graphic xlink:href="pone.0018204.e252.jpg" mimetype="image"/></inline-formula>, and <inline-formula><inline-graphic xlink:href="pone.0018204.e253.jpg" mimetype="image"/></inline-formula> is the total number of different positions that are considered in our model (here, <inline-formula><inline-graphic xlink:href="pone.0018204.e254.jpg" mimetype="image"/></inline-formula> point mutations). In total, the model includes <inline-formula><inline-graphic xlink:href="pone.0018204.e255.jpg" mimetype="image"/></inline-formula> different viral strains <inline-formula><inline-graphic xlink:href="pone.0018204.e256.jpg" mimetype="image"/></inline-formula> that contain point mutations in any pattern of the modelled <inline-formula><inline-graphic xlink:href="pone.0018204.e257.jpg" mimetype="image"/></inline-formula> possible mutations. The phenotype of each mutant strain <inline-formula><inline-graphic xlink:href="pone.0018204.e258.jpg" mimetype="image"/></inline-formula> is modelled by introducing a selective disadvantage <inline-formula><inline-graphic xlink:href="pone.0018204.e259.jpg" mimetype="image"/></inline-formula>, which denotes the loss of functionality (e.g., in the activity of some viral enzyme that is affected by the mutation) relative to the wildtype, and a strain specific inhibitory activity <inline-formula><inline-graphic xlink:href="pone.0018204.e260.jpg" mimetype="image"/></inline-formula> of treatment <inline-formula><inline-graphic xlink:href="pone.0018204.e261.jpg" mimetype="image"/></inline-formula> against the mutant strain <inline-formula><inline-graphic xlink:href="pone.0018204.e262.jpg" mimetype="image"/></inline-formula>. For example, the strain specific infection rate <inline-formula><inline-graphic xlink:href="pone.0018204.e263.jpg" mimetype="image"/></inline-formula> under a certain treatment <inline-formula><inline-graphic xlink:href="pone.0018204.e264.jpg" mimetype="image"/></inline-formula> is given by <inline-formula><inline-graphic xlink:href="pone.0018204.e265.jpg" mimetype="image"/></inline-formula>, where <inline-formula><inline-graphic xlink:href="pone.0018204.e266.jpg" mimetype="image"/></inline-formula> denotes the infection rate constant of the wildtype <inline-formula><inline-graphic xlink:href="pone.0018204.e267.jpg" mimetype="image"/></inline-formula> in the absence of drug <inline-formula><inline-graphic xlink:href="pone.0018204.e268.jpg" mimetype="image"/></inline-formula> (parameters listed in <xref ref-type="table" rid="pone-0018204-t001">Table 1</xref>). The strain-specific specific inhibitory activity is calculated via <inline-formula><inline-graphic xlink:href="pone.0018204.e269.jpg" mimetype="image"/></inline-formula>, where the efficacy of the drugs against the wildtype <inline-formula><inline-graphic xlink:href="pone.0018204.e270.jpg" mimetype="image"/></inline-formula> is generally stated in the corresponding tables and figures (<xref ref-type="fig" rid="pone-0018204-g002">Fig. 2</xref>, <xref ref-type="fig" rid="pone-0018204-g005">Fig. 5</xref> and <xref ref-type="table" rid="pone-0018204-t002">Table 2</xref>) and the resistance of a particular mutant <inline-formula><inline-graphic xlink:href="pone.0018204.e271.jpg" mimetype="image"/></inline-formula> was either set to 1 (100&#x00025; susceptible) or 0.01 (99&#x00025; resistant), if the particular mutant <inline-formula><inline-graphic xlink:href="pone.0018204.e272.jpg" mimetype="image"/></inline-formula>conferred resistance to the particular drug <inline-formula><inline-graphic xlink:href="pone.0018204.e273.jpg" mimetype="image"/></inline-formula>.</p><p>All parameter values have been chosen according to previous studies (see <xref ref-type="table" rid="pone-0018204-t001">Table 1</xref>). The particular viral decay dynamics after application of distinct drug classes were validated in <xref rid="pone.0018204-vonKleist1" ref-type="bibr">[23]</xref>. The model (<xref ref-type="fig" rid="pone-0018204-g001">Fig. 1</xref>) with above described parameters reproduces an average frequency of latently infected cells of <inline-formula><inline-graphic xlink:href="pone.0018204.e274.jpg" mimetype="image"/></inline-formula>
<inline-formula><inline-graphic xlink:href="pone.0018204.e275.jpg" mimetype="image"/></inline-formula> cells (reference range: <inline-formula><inline-graphic xlink:href="pone.0018204.e276.jpg" mimetype="image"/></inline-formula> &#x02013; <inline-formula><inline-graphic xlink:href="pone.0018204.e277.jpg" mimetype="image"/></inline-formula>
<inline-formula><inline-graphic xlink:href="pone.0018204.e278.jpg" mimetype="image"/></inline-formula> cells <xref rid="pone.0018204-Finzi2" ref-type="bibr">[2]</xref>, <xref rid="pone.0018204-Chun3" ref-type="bibr">[7]</xref>, <xref rid="pone.0018204-Blankson1" ref-type="bibr">[30]</xref>, <xref rid="pone.0018204-Fondere1" ref-type="bibr">[31]</xref>), a total of <inline-formula><inline-graphic xlink:href="pone.0018204.e279.jpg" mimetype="image"/></inline-formula> latently infected cells (reference: <inline-formula><inline-graphic xlink:href="pone.0018204.e280.jpg" mimetype="image"/></inline-formula>
<xref rid="pone.0018204-Chun3" ref-type="bibr">[7]</xref>), with a halflife of 20.6 month (average of <xref rid="pone.0018204-Finzi2" ref-type="bibr">[2]</xref>, <xref rid="pone.0018204-Zhang1" ref-type="bibr">[57]</xref>&#x02013;<xref rid="pone.0018204-Ramratnam2" ref-type="bibr">[60]</xref>: 21 month) and a plasma viremia of <inline-formula><inline-graphic xlink:href="pone.0018204.e281.jpg" mimetype="image"/></inline-formula> HIV RNA/mL <xref rid="pone.0018204-Coffin1" ref-type="bibr">[61]</xref> from the latent reservoir.</p></sec><sec id="s4b"><title>Realization and Implementation of the Model</title><p>The overall virus dynamics in our model comprise different viral strains with copy numbers that can vary over several orders of magnitude. For this reason we have chosen a hybrid (stochastic-deterministic) setting for numerical simulation. This approach (i) takes into account stochastic fluctuations in the slow reaction processes; and (ii) reduces the computational costs for the simulation of the fast (deterministic) system dynamics. We used the direct hybrid method proposed in <xref rid="pone.0018204-Alfonsi1" ref-type="bibr">[25]</xref>, where we treated elementary reactions <inline-formula><inline-graphic xlink:href="pone.0018204.e282.jpg" mimetype="image"/></inline-formula> as discrete stochastic processes whenever their propensity function <inline-formula><inline-graphic xlink:href="pone.0018204.e283.jpg" mimetype="image"/></inline-formula> or the quantity of at least one of their reactants was below a threshold of 20. All other reactions were approximated as continuous deterministic processes. Elementary reactions <inline-formula><inline-graphic xlink:href="pone.0018204.e284.jpg" mimetype="image"/></inline-formula> with propensity functions <inline-formula><inline-graphic xlink:href="pone.0018204.e285.jpg" mimetype="image"/></inline-formula> and their respective net changes <inline-formula><inline-graphic xlink:href="pone.0018204.e286.jpg" mimetype="image"/></inline-formula> can be deduced from eqs. (3). For example, the term <inline-formula><inline-graphic xlink:href="pone.0018204.e287.jpg" mimetype="image"/></inline-formula> denotes the infection reaction of T-cells by infectious virus. The propensity function of this reaction is <inline-formula><inline-graphic xlink:href="pone.0018204.e288.jpg" mimetype="image"/></inline-formula>. This reaction changes the species levels as follows: one <inline-formula><inline-graphic xlink:href="pone.0018204.e289.jpg" mimetype="image"/></inline-formula> cell and one <inline-formula><inline-graphic xlink:href="pone.0018204.e290.jpg" mimetype="image"/></inline-formula> virus get consumed (the term is once subtracted from each corresponding ODE), and one <inline-formula><inline-graphic xlink:href="pone.0018204.e291.jpg" mimetype="image"/></inline-formula> cell is produced (the term is once added to the ODE of <inline-formula><inline-graphic xlink:href="pone.0018204.e292.jpg" mimetype="image"/></inline-formula>).</p><p>In brief, the hybrid method comprises the following algorithmic workflow:</p><list list-type="order"><list-item><p>Set initial time <inline-formula><inline-graphic xlink:href="pone.0018204.e293.jpg" mimetype="image"/></inline-formula> and initial number of molecules <inline-formula><inline-graphic xlink:href="pone.0018204.e294.jpg" mimetype="image"/></inline-formula>.</p></list-item><list-item><p>Generate two uniformly distributed pseudo-random variables <inline-formula><inline-graphic xlink:href="pone.0018204.e295.jpg" mimetype="image"/></inline-formula> and <inline-formula><inline-graphic xlink:href="pone.0018204.e296.jpg" mimetype="image"/></inline-formula> on the open unit interval <inline-formula><inline-graphic xlink:href="pone.0018204.e297.jpg" mimetype="image"/></inline-formula> and determine the partitioning of reactions into deterministic and stochastic subsets <inline-formula><inline-graphic xlink:href="pone.0018204.e298.jpg" mimetype="image"/></inline-formula> and <inline-formula><inline-graphic xlink:href="pone.0018204.e299.jpg" mimetype="image"/></inline-formula>, respectively. The latter is realized by comparing the actual propensity and the reactant levels of every reaction with pre-specified thresholds. If one value is below the thresholds, a reaction is included in the stochastic subset <inline-formula><inline-graphic xlink:href="pone.0018204.e300.jpg" mimetype="image"/></inline-formula>, otherwise it is put in the deterministic subset <inline-formula><inline-graphic xlink:href="pone.0018204.e301.jpg" mimetype="image"/></inline-formula>.</p></list-item><list-item><p>Set <inline-formula><inline-graphic xlink:href="pone.0018204.e302.jpg" mimetype="image"/></inline-formula> and solve the ODE system for the deterministic part of the system starting at time <inline-formula><inline-graphic xlink:href="pone.0018204.e303.jpg" mimetype="image"/></inline-formula>
<disp-formula><graphic xlink:href="pone.0018204.e304.jpg" mimetype="image" position="float"/><label>(5)</label></disp-formula>together with<disp-formula><graphic xlink:href="pone.0018204.e305.jpg" mimetype="image" position="float"/><label>(6)</label></disp-formula>until time <inline-formula><inline-graphic xlink:href="pone.0018204.e306.jpg" mimetype="image"/></inline-formula> such that <inline-formula><inline-graphic xlink:href="pone.0018204.e307.jpg" mimetype="image"/></inline-formula>.</p></list-item><list-item><p>Take the integer <inline-formula><inline-graphic xlink:href="pone.0018204.e308.jpg" mimetype="image"/></inline-formula> satisfying<disp-formula><graphic xlink:href="pone.0018204.e309.jpg" mimetype="image" position="float"/><label>(7)</label></disp-formula>in order to determine the stochastic reaction <inline-formula><inline-graphic xlink:href="pone.0018204.e310.jpg" mimetype="image"/></inline-formula> to be performed.</p></list-item><list-item><p>Update <inline-formula><inline-graphic xlink:href="pone.0018204.e311.jpg" mimetype="image"/></inline-formula> according to reaction <inline-formula><inline-graphic xlink:href="pone.0018204.e312.jpg" mimetype="image"/></inline-formula>, hence set <inline-formula><inline-graphic xlink:href="pone.0018204.e313.jpg" mimetype="image"/></inline-formula>.</p></list-item><list-item><p>Set <inline-formula><inline-graphic xlink:href="pone.0018204.e314.jpg" mimetype="image"/></inline-formula>, and stop the procedure if the final time is reached. Otherwise go to Step (2).</p></list-item></list><p>The above algorithmic scheme requires the use of numerical integrators that allow to stop integration in step (3) when a stochastic reaction event is detected at a time <inline-formula><inline-graphic xlink:href="pone.0018204.e315.jpg" mimetype="image"/></inline-formula> where <inline-formula><inline-graphic xlink:href="pone.0018204.e316.jpg" mimetype="image"/></inline-formula>. The utilized integrator is based on numerical differentiation formulas <xref rid="pone.0018204-Klopfenstein1" ref-type="bibr">[62]</xref>, and uses strategies for event detection and error- and step size control comparable to ode15s in M<sc>atlab</sc>
<xref rid="pone.0018204-Shampine1" ref-type="bibr">[63]</xref>. To generate the data for <xref ref-type="fig" rid="pone-0018204-g004">Fig. 4</xref>, we performed 12000 hybrid simulations in total. With realization start (<inline-formula><inline-graphic xlink:href="pone.0018204.e317.jpg" mimetype="image"/></inline-formula>) the effects of drug treatment were simulated, until <inline-formula><inline-graphic xlink:href="pone.0018204.e318.jpg" mimetype="image"/></inline-formula> days was reached. Every numerical calculation was computed with a relative error tolerance of 10<sup>&#x02212;6</sup> and an absolute error tolerance of 10<sup>&#x02212;9</sup>. Our simulation code is provided in <xref ref-type="supplementary-material" rid="pone.0018204.s003">Source Code S1</xref>&#x02013;<xref ref-type="supplementary-material" rid="pone.0018204.s008">S6</xref>.</p></sec><sec id="s4c"><title>Reproductive Numbers</title><p>For the model above (eq. (3)), the reproductive numbers, which indicate the expected number of offspring in the next generation, are defined as follows: the reproductive number <inline-formula><inline-graphic xlink:href="pone.0018204.e319.jpg" mimetype="image"/></inline-formula> of a single virus of strain <inline-formula><inline-graphic xlink:href="pone.0018204.e320.jpg" mimetype="image"/></inline-formula> under treatment <inline-formula><inline-graphic xlink:href="pone.0018204.e321.jpg" mimetype="image"/></inline-formula> is given by <disp-formula><graphic xlink:href="pone.0018204.e322.jpg" mimetype="image" position="float"/></disp-formula>with constants<disp-formula><graphic xlink:href="pone.0018204.e323.jpg" mimetype="image" position="float"/></disp-formula>
<disp-formula><graphic xlink:href="pone.0018204.e324.jpg" mimetype="image" position="float"/></disp-formula>
<disp-formula><graphic xlink:href="pone.0018204.e325.jpg" mimetype="image" position="float"/></disp-formula>
</p><p>Since infected cells are also pathogens, which can lead to a rebound of the disease even in the absence of any virus, we also determined their basic reproductive numbers under a given treatment <inline-formula><inline-graphic xlink:href="pone.0018204.e326.jpg" mimetype="image"/></inline-formula>. The basic reproductive numbers <inline-formula><inline-graphic xlink:href="pone.0018204.e327.jpg" mimetype="image"/></inline-formula> and <inline-formula><inline-graphic xlink:href="pone.0018204.e328.jpg" mimetype="image"/></inline-formula> of the infectious stages <inline-formula><inline-graphic xlink:href="pone.0018204.e329.jpg" mimetype="image"/></inline-formula> and <inline-formula><inline-graphic xlink:href="pone.0018204.e330.jpg" mimetype="image"/></inline-formula>, associated with the viral strain <inline-formula><inline-graphic xlink:href="pone.0018204.e331.jpg" mimetype="image"/></inline-formula>, are given by <disp-formula><graphic xlink:href="pone.0018204.e332.jpg" mimetype="image" position="float"/></disp-formula>
<disp-formula><graphic xlink:href="pone.0018204.e333.jpg" mimetype="image" position="float"/></disp-formula>Finally, the reproductive numbers <inline-formula><inline-graphic xlink:href="pone.0018204.e334.jpg" mimetype="image"/></inline-formula> and <inline-formula><inline-graphic xlink:href="pone.0018204.e335.jpg" mimetype="image"/></inline-formula> of the infectious stages <inline-formula><inline-graphic xlink:href="pone.0018204.e336.jpg" mimetype="image"/></inline-formula> and <inline-formula><inline-graphic xlink:href="pone.0018204.e337.jpg" mimetype="image"/></inline-formula>, associated with the viral strain <inline-formula><inline-graphic xlink:href="pone.0018204.e338.jpg" mimetype="image"/></inline-formula>, are given by <disp-formula><graphic xlink:href="pone.0018204.e339.jpg" mimetype="image" position="float"/></disp-formula>
<disp-formula><graphic xlink:href="pone.0018204.e340.jpg" mimetype="image" position="float"/></disp-formula>
<disp-formula><graphic xlink:href="pone.0018204.e341.jpg" mimetype="image" position="float"/></disp-formula>
</p></sec><sec id="s4d"><title>Reproductive Capacity</title><p>We have previously introduced the reproductive capacity <inline-formula><inline-graphic xlink:href="pone.0018204.e342.jpg" mimetype="image"/></inline-formula>
<xref rid="pone.0018204-vonKleist1" ref-type="bibr">[23]</xref>, which can be interpreted as the expected total number of infectious offspring that the infection produces in one round of replication under a certain treatment <inline-formula><inline-graphic xlink:href="pone.0018204.e343.jpg" mimetype="image"/></inline-formula>, given the current state of the infection. In this article, we utilize the reproductive capacity in order to get individual treatment switching times (see eq. (1), main article), which are displayed in <xref ref-type="fig" rid="pone-0018204-g003">Fig. 3</xref>. The reproductive capacity of the entire quasi-species ensemble under treatment <inline-formula><inline-graphic xlink:href="pone.0018204.e344.jpg" mimetype="image"/></inline-formula> is defined as the weighted sum of the basic reproductive numbers of all pathogenic stages of mutant strain <inline-formula><inline-graphic xlink:href="pone.0018204.e345.jpg" mimetype="image"/></inline-formula>, i.e., free virus, infected T-cells and infected macrophages, weighted by the abundance of the corresponding pathogenic stage <xref rid="pone.0018204-vonKleist1" ref-type="bibr">[23]</xref>:<disp-formula><graphic xlink:href="pone.0018204.e346.jpg" mimetype="image" position="float"/></disp-formula>where <inline-formula><inline-graphic xlink:href="pone.0018204.e347.jpg" mimetype="image"/></inline-formula> and <inline-formula><inline-graphic xlink:href="pone.0018204.e348.jpg" mimetype="image"/></inline-formula> are the strain-specific reproductive numbers of the different infective compartments (see previous sections).</p></sec></sec><sec sec-type="supplementary-material" id="s5"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0018204.s001"><label>Figure S1</label><caption><p>
<bold>Time and probability of virological failure depends on pool-size of archived drug-resistant virus.</bold> A: The median time until virological failure, in relation to the number of fully-resistant archived virus (fully &#x0200a;=&#x0200a; resistant against all drugs in the triple-drug combination). B: Probability that virological failure occurs within two years after initiation of HAART therapy as a function of the number of fully-resistant archived virus. 500 stochastic-deterministic runs were performed for each pool size of the latently infected drug-resistant reservoir. Parameter values used: <inline-formula><inline-graphic xlink:href="pone.0018204.e349.jpg" mimetype="image"/></inline-formula>&#x0200a;=&#x0200a;0.75, <inline-formula><inline-graphic xlink:href="pone.0018204.e350.jpg" mimetype="image"/></inline-formula>&#x0200a;=&#x0200a;0.8.</p><p>(PDF)</p></caption><media xlink:href="pone.0018204.s001.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0018204.s002"><label>Table S1</label><caption><p>
<bold>Determination of relevant parameter space for further investigation.</bold> We assessed virological failure rates after one year of triple drug therapy for varying values of efficacy <inline-formula><inline-graphic xlink:href="pone.0018204.e351.jpg" mimetype="image"/></inline-formula> of drug <inline-formula><inline-graphic xlink:href="pone.0018204.e352.jpg" mimetype="image"/></inline-formula> against the wildtype <inline-formula><inline-graphic xlink:href="pone.0018204.e353.jpg" mimetype="image"/></inline-formula> and selective disadvantage per mutation <inline-formula><inline-graphic xlink:href="pone.0018204.e354.jpg" mimetype="image"/></inline-formula>. All other parameters have been taken from <xref ref-type="table" rid="pone-0018204-t001">Table 1</xref>. A parameter combination (in terms of <inline-formula><inline-graphic xlink:href="pone.0018204.e355.jpg" mimetype="image"/></inline-formula> and <inline-formula><inline-graphic xlink:href="pone.0018204.e356.jpg" mimetype="image"/></inline-formula>) was considered relevant, if it produced realistic failure rates after one year of therapy <xref rid="pone.0018204-Riddler1" ref-type="bibr">[29]</xref>. Confidence ranges are indicated in brackets and were calculated using Greenwood's formula. Each condition has been evaluated by 100 stochastic deterministic simulations.</p><p>(PDF)</p></caption><media xlink:href="pone.0018204.s002.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0018204.s003"><label>Source Code S1</label><caption><p>The File &#x02018;HAART.m&#x02019; can be used to simulate the kinetics of HIV after application of conventional HAART treatment in MATLAB.</p><p>(M)</p></caption><media xlink:href="pone.0018204.s003.m"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0018204.s004"><label>Source Code S2</label><caption><p>The File &#x02018;HIVmodel.m&#x02019; builds the original HIV model used throughout the manuscript for use in MATLAB.</p><p>(M)</p></caption><media xlink:href="pone.0018204.s004.m"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0018204.s005"><label>Source Code S3</label><caption><p>The File &#x02018;InductionMaintenance.m&#x02019; can be used to simulate the kinetics of HIV after under the proposed induction-maintenance therapy in MATLAB.</p><p>(M)</p></caption><media xlink:href="pone.0018204.s005.m"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0018204.s006"><label>Source Code S4</label><caption><p>The File &#x02018;PatientMonitoring.m&#x02019; contains the MATLAB implementation of routine patient monitoring.</p><p>(M)</p></caption><media xlink:href="pone.0018204.s006.m"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0018204.s007"><label>Source Code S5</label><caption><p>The File &#x02018;ReadMeFirst.txt&#x02019; Contains a description of all supplied source code files, contact details, information on runtime and execution and a copy of the GNU public license.</p><p>(TXT)</p></caption><media xlink:href="pone.0018204.s007.txt"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0018204.s008"><label>Source Code S6</label><caption><p>The File &#x02018;SpeciesLevelsIndices.pdf&#x02019; contains an interpretation of the output generated by executing the provided MATLAB Source Code Files (<xref ref-type="supplementary-material" rid="pone.0018204.s003">Source Code S1</xref>&#x02013;<xref ref-type="supplementary-material" rid="pone.0018204.s006">S4</xref>).</p><p>(PDF)</p></caption><media xlink:href="pone.0018204.s008.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>The authors would like to thank Prof. Karin M&#x000f6;lling (Head of Virology Dep., University Z&#x000fc;rich, Switzerland) for helpful comments regarding the manuscript. We are very grateful to the National University of Ireland in Maynooth for providing the high-performance computing cluster. Special thanks to Vanush Misha Paturyan for assistance in scheduling jobs on the computing cluster.</p></ack><fn-group><fn fn-type="COI-statement"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>MvK acknowledges financial support by BMBF funding. SM acknowledges financial support by DFG funding, provided through the Dahlem Research School of Freie Universit&#x000e4;t Berlin. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></fn></fn-group><ref-list><title>References</title><ref id="pone.0018204-Finzi1"><label>1</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Finzi</surname><given-names>D</given-names></name><name><surname>Hermankova</surname><given-names>M</given-names></name><name><surname>Pierson</surname><given-names>T</given-names></name><name><surname>Carruth</surname><given-names>LM</given-names></name><name><surname>Buck</surname><given-names>C</given-names></name><etal/></person-group>
<year>1997</year>
<article-title>Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy.</article-title>
<source>Science</source>
<volume>278</volume>
<fpage>1295</fpage>
<lpage>1300</lpage>
<pub-id pub-id-type="pmid">9360927</pub-id></element-citation></ref><ref id="pone.0018204-Finzi2"><label>2</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Finzi</surname><given-names>D</given-names></name><name><surname>Blankson</surname><given-names>J</given-names></name><name><surname>Siliciano</surname><given-names>JD</given-names></name><name><surname>Margolick</surname><given-names>JB</given-names></name><name><surname>Chadwick</surname><given-names>K</given-names></name><etal/></person-group>
<year>1999</year>
<article-title>Latent infection of CD4&#x0002b; T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy.</article-title>
<source>Nat Med</source>
<volume>5</volume>
<fpage>512</fpage>
<lpage>517</lpage>
<pub-id pub-id-type="pmid">10229227</pub-id></element-citation></ref><ref id="pone.0018204-Wong1"><label>3</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wong</surname><given-names>JK</given-names></name><name><surname>Hezareh</surname><given-names>M</given-names></name><name><surname>G&#x000fc;nthard</surname><given-names>HF</given-names></name><name><surname>Havlir</surname><given-names>DV</given-names></name><name><surname>Ignacio</surname><given-names>CC</given-names></name><etal/></person-group>
<year>1997</year>
<article-title>Recovery of replication-competent HIV despite prolonged suppression of plasma viremia.</article-title>
<source>Science</source>
<volume>278</volume>
<fpage>1291</fpage>
<lpage>1295</lpage>
<pub-id pub-id-type="pmid">9360926</pub-id></element-citation></ref><ref id="pone.0018204-Carter1"><label>4</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Carter</surname><given-names>CC</given-names></name><name><surname>Onafuwa-Nuga</surname><given-names>A</given-names></name><name><surname>McNamara</surname><given-names>LA</given-names></name><name><surname>Riddell</surname><given-names>J</given-names></name><name><surname>Bixby</surname><given-names>D</given-names></name><etal/></person-group>
<year>2010</year>
<article-title>HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs.</article-title>
<source>Nat Med</source>
<volume>16</volume>
<fpage>446</fpage>
<lpage>451</lpage>
<pub-id pub-id-type="pmid">20208541</pub-id></element-citation></ref><ref id="pone.0018204-Chun1"><label>5</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chun</surname><given-names>TW</given-names></name><name><surname>Finzi</surname><given-names>D</given-names></name><name><surname>Margolick</surname><given-names>J</given-names></name><name><surname>Chadwick</surname><given-names>K</given-names></name><name><surname>Schwartz</surname><given-names>D</given-names></name><etal/></person-group>
<year>1995</year>
<article-title>In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency.</article-title>
<source>Nat Med</source>
<volume>1</volume>
<fpage>1284</fpage>
<lpage>1290</lpage>
<pub-id pub-id-type="pmid">7489410</pub-id></element-citation></ref><ref id="pone.0018204-Chun2"><label>6</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chun</surname><given-names>TW</given-names></name><name><surname>Stuyver</surname><given-names>L</given-names></name><name><surname>Mizell</surname><given-names>SB</given-names></name><name><surname>Ehler</surname><given-names>LA</given-names></name><name><surname>Mican</surname><given-names>JA</given-names></name><etal/></person-group>
<year>1997</year>
<article-title>Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy.</article-title>
<source>Proc Natl Acad Sci U S A</source>
<volume>94</volume>
<fpage>13193</fpage>
<lpage>13197</lpage>
<pub-id pub-id-type="pmid">9371822</pub-id></element-citation></ref><ref id="pone.0018204-Chun3"><label>7</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chun</surname><given-names>TW</given-names></name><name><surname>Carruth</surname><given-names>L</given-names></name><name><surname>Finzi</surname><given-names>D</given-names></name><name><surname>Shen</surname><given-names>X</given-names></name><name><surname>DiGiuseppe</surname><given-names>JA</given-names></name><etal/></person-group>
<year>1997</year>
<article-title>Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection.</article-title>
<source>Nature</source>
<volume>387</volume>
<fpage>183</fpage>
<lpage>188</lpage>
<pub-id pub-id-type="pmid">9144289</pub-id></element-citation></ref><ref id="pone.0018204-Pierson1"><label>8</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pierson</surname><given-names>T</given-names></name><name><surname>McArthur</surname><given-names>J</given-names></name><name><surname>Siliciano</surname><given-names>RF</given-names></name></person-group>
<year>2000</year>
<article-title>Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.</article-title>
<source>Annu Rev Immunol</source>
<volume>18</volume>
<fpage>665</fpage>
<lpage>708</lpage>
<pub-id pub-id-type="pmid">10837072</pub-id></element-citation></ref><ref id="pone.0018204-Siliciano1"><label>9</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Siliciano</surname><given-names>JD</given-names></name><name><surname>Siliciano</surname><given-names>RF</given-names></name></person-group>
<year>2004</year>
<article-title>A long-term latent reservoir for HIV-1: discovery and clinical implications.</article-title>
<source>J Antimicrob Chemother</source>
<volume>54</volume>
<fpage>6</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">15163657</pub-id></element-citation></ref><ref id="pone.0018204-Lambotte1"><label>10</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lambotte</surname><given-names>O</given-names></name><name><surname>Chaix</surname><given-names>ML</given-names></name><name><surname>Gubler</surname><given-names>B</given-names></name><name><surname>Nasreddine</surname><given-names>N</given-names></name><name><surname>Wallon</surname><given-names>C</given-names></name><etal/></person-group>
<year>2004</year>
<article-title>The lymphocyte HIV reservoir in patients on long-term HAART is a memory of virus evolution.</article-title>
<source>AIDS</source>
<volume>18</volume>
<fpage>1147</fpage>
<lpage>1158</lpage>
<pub-id pub-id-type="pmid">15166530</pub-id></element-citation></ref><ref id="pone.0018204-Reekie1"><label>11</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Reekie</surname><given-names>J</given-names></name><name><surname>Mocroft</surname><given-names>A</given-names></name><name><surname>Ledergerber</surname><given-names>B</given-names></name><name><surname>Beniowski</surname><given-names>M</given-names></name><name><surname>Clotet</surname><given-names>B</given-names></name><etal/></person-group>
<year>2010</year>
<article-title>History of viral suppression on combination antiretroviral therapy as a predictor of virological failure after a treatment change.</article-title>
<source>HIV Med</source>
<volume>11</volume>
<fpage>469</fpage>
<lpage>478</lpage>
<pub-id pub-id-type="pmid">20201975</pub-id></element-citation></ref><ref id="pone.0018204-Ho1"><label>12</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ho</surname><given-names>DD</given-names></name><name><surname>Neumann</surname><given-names>AU</given-names></name><name><surname>Perelson</surname><given-names>AS</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Leonard</surname><given-names>JM</given-names></name><etal/></person-group>
<year>1995</year>
<article-title>Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection.</article-title>
<source>Nature</source>
<volume>373</volume>
<fpage>123</fpage>
<lpage>126</lpage>
<pub-id pub-id-type="pmid">7816094</pub-id></element-citation></ref><ref id="pone.0018204-Blumberg1"><label>13</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Blumberg</surname><given-names>HM</given-names></name><name><surname>Leonard</surname><given-names>MK</given-names></name><name><surname>Jasmer</surname><given-names>RM</given-names></name></person-group>
<year>2005</year>
<article-title>Update on the treatment of tuberculosis and latent tuberculosis infection.</article-title>
<source>JAMA</source>
<volume>293</volume>
<fpage>2776</fpage>
<lpage>2784</lpage>
<pub-id pub-id-type="pmid">15941808</pub-id></element-citation></ref><ref id="pone.0018204-Horstkotte1"><label>14</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Horstkotte</surname><given-names>D</given-names></name><name><surname>Follath</surname><given-names>F</given-names></name><name><surname>Gutschik</surname><given-names>E</given-names></name><name><surname>Lengyel</surname><given-names>M</given-names></name><name><surname>Oto</surname><given-names>A</given-names></name><etal/></person-group>
<year>2004</year>
<article-title>Guidelines on prevention, diagnosis and treatment of infective endocarditis executive summary; the task force on infective endocarditis of the european society of cardiology.</article-title>
<source>Eur Heart J</source>
<volume>25</volume>
<fpage>267</fpage>
<lpage>276</lpage>
<pub-id pub-id-type="pmid">14972429</pub-id></element-citation></ref><ref id="pone.0018204-Zimmerli1"><label>15</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zimmerli</surname><given-names>W</given-names></name><name><surname>Ochsner</surname><given-names>PE</given-names></name></person-group>
<year>2003</year>
<article-title>Management of infection associated with prosthetic joints.</article-title>
<source>Infection</source>
<volume>31</volume>
<fpage>99</fpage>
<lpage>108</lpage>
<pub-id pub-id-type="pmid">12682815</pub-id></element-citation></ref><ref id="pone.0018204-Curlin1"><label>16</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Curlin</surname><given-names>ME</given-names></name><name><surname>Iyer</surname><given-names>S</given-names></name><name><surname>Mittler</surname><given-names>JE</given-names></name></person-group>
<year>2007</year>
<article-title>Optimal timing and duration of induction therapy for HIV-1 infection.</article-title>
<source>PLoS Comput Biol</source>
<volume>3</volume>
<fpage>e133</fpage>
<pub-id pub-id-type="pmid">17630827</pub-id></element-citation></ref><ref id="pone.0018204-Catanzaro1"><label>17</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Catanzaro</surname><given-names>LM</given-names></name><name><surname>Slish</surname><given-names>JC</given-names></name><name><surname>DiCenzo</surname><given-names>R</given-names></name><name><surname>Morse</surname><given-names>GD</given-names></name></person-group>
<year>2004</year>
<article-title>Drug interactions with antiretrovirals.</article-title>
<source>Curr HIV/AIDS Rep</source>
<volume>1</volume>
<fpage>89</fpage>
<lpage>96</lpage>
<pub-id pub-id-type="pmid">16091228</pub-id></element-citation></ref><ref id="pone.0018204-Carr1"><label>18</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Carr</surname><given-names>A</given-names></name></person-group>
<year>2003</year>
<article-title>Toxicity of antiretroviral therapy and implications for drug development.</article-title>
<source>Nat Rev Drug Discov</source>
<volume>2</volume>
<fpage>624</fpage>
<lpage>634</lpage>
<pub-id pub-id-type="pmid">12904812</pub-id></element-citation></ref><ref id="pone.0018204-DAmato1"><label>19</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>D'Amato</surname><given-names>RM</given-names></name><name><surname>D'Aquila</surname><given-names>RT</given-names></name><name><surname>Wein</surname><given-names>LM</given-names></name></person-group>
<year>1998</year>
<article-title>Management of antiretroviral therapy for HIV infection: modelling when to change therapy.</article-title>
<source>Antivir Ther</source>
<volume>3</volume>
<fpage>147</fpage>
<lpage>158</lpage>
<pub-id pub-id-type="pmid">10682132</pub-id></element-citation></ref><ref id="pone.0018204-MartinezPicado1"><label>20</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Martinez-Picado</surname><given-names>J</given-names></name><name><surname>Negredo</surname><given-names>E</given-names></name><name><surname>Ruiz</surname><given-names>L</given-names></name><name><surname>Shintani</surname><given-names>A</given-names></name><name><surname>Fumaz</surname><given-names>CR</given-names></name><etal/></person-group>
<year>2003</year>
<article-title>Alternation of antiretroviral drug regimens for HIV infection. A randomized, controlled trial.</article-title>
<source>Ann Intern Med</source>
<volume>139</volume>
<fpage>81</fpage>
<lpage>89</lpage>
<pub-id pub-id-type="pmid">12859157</pub-id></element-citation></ref><ref id="pone.0018204-Negredo1"><label>21</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Negredo</surname><given-names>E</given-names></name><name><surname>Paredes</surname><given-names>R</given-names></name><name><surname>Peraire</surname><given-names>J</given-names></name><name><surname>Pedrol</surname><given-names>E</given-names></name><name><surname>C&#x000f4;t&#x000e9;</surname><given-names>H</given-names></name><etal/></person-group>
<year>2004</year>
<article-title>Alternation of antiretroviral drug regimens for HIV infection. efficacy, safety and tolerability at week 96 of the Swatch study.</article-title>
<source>Antivir Ther</source>
<volume>9</volume>
<fpage>889</fpage>
<lpage>893</lpage>
<pub-id pub-id-type="pmid">15651747</pub-id></element-citation></ref><ref id="pone.0018204-Sherr1"><label>22</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sherr</surname><given-names>L</given-names></name><name><surname>Lampe</surname><given-names>F</given-names></name><name><surname>Norwood</surname><given-names>S</given-names></name><name><surname>Leake-Date</surname><given-names>H</given-names></name><name><surname>Fisher</surname><given-names>M</given-names></name><etal/></person-group>
<year>2007</year>
<article-title>Successive switching of antiretroviral therapy is associated with high psychological and physical burden.</article-title>
<source>Int J STD AIDS</source>
<volume>18</volume>
<fpage>700</fpage>
<lpage>704</lpage>
<pub-id pub-id-type="pmid">17945049</pub-id></element-citation></ref><ref id="pone.0018204-vonKleist1"><label>23</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>von Kleist</surname><given-names>M</given-names></name><name><surname>Menz</surname><given-names>S</given-names></name><name><surname>Huisinga</surname><given-names>W</given-names></name></person-group>
<year>2010</year>
<article-title>Drug-class specific impact of antivirals on the reproductive capacity of HIV.</article-title>
<source>PLoS Comput Biol</source>
<volume>6</volume>
<fpage>e1000720</fpage>
<pub-id pub-id-type="pmid">20361047</pub-id></element-citation></ref><ref id="pone.0018204-Panel1"><label>24</label><element-citation publication-type="book">
<article-title>Panel on Antiretroviral Guidelines for Adults and Adolescents.</article-title>
<source>Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents</source>
<publisher-name>Department of Health and Human Services </publisher-name>
<fpage>1</fpage>
<lpage>161</lpage>
<comment>December 1, 2009. (<ext-link ext-link-type="uri" xlink:href="http://www.aidsinfo.nih.gov/contentfiles/adultandadolescentgl.pdf">http://www.aidsinfo.nih.gov/contentfiles/adultandadolescentgl.pdf</ext-link>) (accessed 01-Oct-2010) </comment>
</element-citation></ref><ref id="pone.0018204-Alfonsi1"><label>25</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Alfonsi</surname><given-names>A</given-names></name><name><surname>Canc&#x000e8;s</surname><given-names>E</given-names></name><name><surname>Turinici</surname><given-names>G</given-names></name><name><surname>Ventura</surname><given-names>B</given-names></name><name><surname>Huisinga</surname><given-names>W</given-names></name></person-group>
<year>2005</year>
<article-title>Exact simulation of hybrid stochastic and deterministic models for biochemical systems.</article-title>
<source>ESAIM Proc</source>
<volume>14</volume>
<fpage>1</fpage>
<lpage>23</lpage>
</element-citation></ref><ref id="pone.0018204-Fabbiani1"><label>26</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fabbiani</surname><given-names>M</given-names></name><name><surname>Giambenedetto</surname><given-names>SD</given-names></name><name><surname>Bracciale</surname><given-names>L</given-names></name><name><surname>Bacarelli</surname><given-names>A</given-names></name><name><surname>Ragazzoni</surname><given-names>E</given-names></name><etal/></person-group>
<year>2009</year>
<article-title>Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: 2 years of experience in routine clinical practice.</article-title>
<source>J Antimicrob Chemother</source>
<volume>64</volume>
<fpage>109</fpage>
<lpage>117</lpage>
<pub-id pub-id-type="pmid">19398461</pub-id></element-citation></ref><ref id="pone.0018204-Clavel1"><label>27</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Clavel</surname><given-names>F</given-names></name><name><surname>Hance</surname><given-names>AJ</given-names></name></person-group>
<year>2004</year>
<article-title>HIV drug resistance.</article-title>
<source>N Engl J Med</source>
<volume>350</volume>
<fpage>1023</fpage>
<lpage>1035</lpage>
<pub-id pub-id-type="pmid">14999114</pub-id></element-citation></ref><ref id="pone.0018204-Clavel2"><label>28</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Clavel</surname><given-names>F</given-names></name></person-group>
<year>2009</year>
<article-title>HIV resistance to raltegravir.</article-title>
<source>Eur J Med Res</source>
<volume>14</volume>
<issue>Suppl 3</issue>
<fpage>47</fpage>
<lpage>54</lpage>
</element-citation></ref><ref id="pone.0018204-Riddler1"><label>29</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Riddler</surname><given-names>SA</given-names></name><name><surname>Haubrich</surname><given-names>R</given-names></name><name><surname>DiRienzo</surname><given-names>AG</given-names></name><name><surname>Peeples</surname><given-names>L</given-names></name><name><surname>Powderly</surname><given-names>WG</given-names></name><etal/></person-group>
<year>2008</year>
<article-title>Class-sparing regimens for initial treatment of HIV-1 infection.</article-title>
<source>N Engl J Med</source>
<volume>358</volume>
<fpage>2095</fpage>
<lpage>2106</lpage>
<pub-id pub-id-type="pmid">18480202</pub-id></element-citation></ref><ref id="pone.0018204-Blankson1"><label>30</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Blankson</surname><given-names>JN</given-names></name><name><surname>Finzi</surname><given-names>D</given-names></name><name><surname>Pierson</surname><given-names>TC</given-names></name><name><surname>Sabundayo</surname><given-names>BP</given-names></name><name><surname>Chadwick</surname><given-names>K</given-names></name><etal/></person-group>
<year>2000</year>
<article-title>Biphasic decay of latently infected CD4&#x0002b; T cells in acute human immunodeficiency virus type 1 infection.</article-title>
<source>J Infect Dis</source>
<volume>182</volume>
<fpage>1636</fpage>
<lpage>1642</lpage>
<pub-id pub-id-type="pmid">11069234</pub-id></element-citation></ref><ref id="pone.0018204-Fondere1"><label>31</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fondere</surname><given-names>JM</given-names></name><name><surname>Planas</surname><given-names>JF</given-names></name><name><surname>Huguet</surname><given-names>MF</given-names></name><name><surname>Baillat</surname><given-names>V</given-names></name><name><surname>Bolos</surname><given-names>F</given-names></name><etal/></person-group>
<year>2004</year>
<article-title>Enumeration of latently infected CD4&#x0002b; T cells from HIV-1-infected patients using an HIV-1 antigen ELISPOT assay.</article-title>
<source>J Clin Virol</source>
<volume>29</volume>
<fpage>33</fpage>
<lpage>38</lpage>
<pub-id pub-id-type="pmid">14675867</pub-id></element-citation></ref><ref id="pone.0018204-Richman1"><label>32</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Richman</surname><given-names>DD</given-names></name></person-group>
<year>2000</year>
<article-title>Principles of HIV resistance testing and overview of assay performance characteristics.</article-title>
<source>Antivir Ther</source>
<volume>5</volume>
<fpage>27</fpage>
<lpage>31</lpage>
<pub-id pub-id-type="pmid">10846590</pub-id></element-citation></ref><ref id="pone.0018204-Eriksson1"><label>33</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Eriksson</surname><given-names>N</given-names></name><name><surname>Pachter</surname><given-names>L</given-names></name><name><surname>Mitsuya</surname><given-names>Y</given-names></name><name><surname>Rhee</surname><given-names>SY</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><etal/></person-group>
<year>2008</year>
<article-title>Viral population estimation using pyrosequencing.</article-title>
<source>PLoS Comput Biol</source>
<volume>4</volume>
<fpage>e1000074</fpage>
<pub-id pub-id-type="pmid">18437230</pub-id></element-citation></ref><ref id="pone.0018204-Nijhuis1"><label>34</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nijhuis</surname><given-names>M</given-names></name><name><surname>Schuurman</surname><given-names>R</given-names></name><name><surname>de Jong</surname><given-names>D</given-names></name><name><surname>Erickson</surname><given-names>J</given-names></name><name><surname>Gustchina</surname><given-names>E</given-names></name><etal/></person-group>
<year>1999</year>
<article-title>Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy.</article-title>
<source>AIDS</source>
<volume>13</volume>
<fpage>2349</fpage>
<lpage>2359</lpage>
<pub-id pub-id-type="pmid">10597776</pub-id></element-citation></ref><ref id="pone.0018204-Arora1"><label>35</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Arora</surname><given-names>P</given-names></name><name><surname>Dixit</surname><given-names>NM</given-names></name></person-group>
<year>2009</year>
<article-title>Timing the emergence of resistance to anti-HIV drugs with large genetic barriers.</article-title>
<source>PLoS Comput Biol</source>
<volume>5</volume>
<fpage>e1000305</fpage>
<pub-id pub-id-type="pmid">19282958</pub-id></element-citation></ref><ref id="pone.0018204-Markowitz1"><label>36</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Markowitz</surname><given-names>M</given-names></name><name><surname>Louie</surname><given-names>M</given-names></name><name><surname>Hurley</surname><given-names>A</given-names></name><name><surname>Sun</surname><given-names>E</given-names></name><name><surname>Mascio</surname><given-names>MD</given-names></name><etal/></person-group>
<year>2003</year>
<article-title>A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo.</article-title>
<source>J Virol</source>
<volume>77</volume>
<fpage>5037</fpage>
<lpage>5038</lpage>
<pub-id pub-id-type="pmid">12663814</pub-id></element-citation></ref><ref id="pone.0018204-Perelson1"><label>37</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Perelson</surname><given-names>AS</given-names></name><name><surname>Neumann</surname><given-names>AU</given-names></name><name><surname>Markowitz</surname><given-names>M</given-names></name><name><surname>Leonard</surname><given-names>JM</given-names></name><name><surname>Ho</surname><given-names>DD</given-names></name></person-group>
<year>1996</year>
<article-title>HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time.</article-title>
<source>Science</source>
<volume>271</volume>
<fpage>1582</fpage>
<lpage>1586</lpage>
<pub-id pub-id-type="pmid">8599114</pub-id></element-citation></ref><ref id="pone.0018204-Perelson2"><label>38</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Perelson</surname><given-names>AS</given-names></name><name><surname>Essunger</surname><given-names>P</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Vesanen</surname><given-names>M</given-names></name><name><surname>Hurley</surname><given-names>A</given-names></name><etal/></person-group>
<year>1997</year>
<article-title>Decay characteristics of HIV-1-infected compartments during combination therapy.</article-title>
<source>Nature</source>
<volume>387</volume>
<fpage>188</fpage>
<lpage>191</lpage>
<pub-id pub-id-type="pmid">9144290</pub-id></element-citation></ref><ref id="pone.0018204-Ji1"><label>39</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ji</surname><given-names>H</given-names></name><name><surname>Mass&#x000e9;</surname><given-names>N</given-names></name><name><surname>Tyler</surname><given-names>S</given-names></name><name><surname>Liang</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><etal/></person-group>
<year>2010</year>
<article-title>HIV drug resistance surveillance using pooled pyrosequencing.</article-title>
<source>PLoS One</source>
<volume>5</volume>
<fpage>e9263</fpage>
<pub-id pub-id-type="pmid">20174661</pub-id></element-citation></ref><ref id="pone.0018204-Archer1"><label>40</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Archer</surname><given-names>J</given-names></name><name><surname>Braverman</surname><given-names>MS</given-names></name><name><surname>Taillon</surname><given-names>BE</given-names></name><name><surname>Desany</surname><given-names>B</given-names></name><name><surname>James</surname><given-names>I</given-names></name><etal/></person-group>
<year>2009</year>
<article-title>Detection of low-frequency pretherapy chemokine (CXC motif) receptor 4 (CXCR4)-using HIV-1 with ultra-deep pyrosequencing.</article-title>
<source>AIDS</source>
<volume>23</volume>
<fpage>1209</fpage>
<lpage>1218</lpage>
<pub-id pub-id-type="pmid">19424056</pub-id></element-citation></ref><ref id="pone.0018204-Ribeiro1"><label>41</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ribeiro</surname><given-names>RM</given-names></name><name><surname>Bonhoeffer</surname><given-names>S</given-names></name><name><surname>Nowak</surname><given-names>MA</given-names></name></person-group>
<year>1998</year>
<article-title>The frequency of resistant mutant virus before antiviral therapy.</article-title>
<source>AIDS</source>
<volume>12</volume>
<fpage>461</fpage>
<lpage>465</lpage>
<pub-id pub-id-type="pmid">9543443</pub-id></element-citation></ref><ref id="pone.0018204-Mansky1"><label>42</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mansky</surname><given-names>LM</given-names></name><name><surname>Temin</surname><given-names>HM</given-names></name></person-group>
<year>1995</year>
<article-title>Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase.</article-title>
<source>J Virol</source>
<volume>69</volume>
<fpage>5087</fpage>
<lpage>5094</lpage>
<pub-id pub-id-type="pmid">7541846</pub-id></element-citation></ref><ref id="pone.0018204-MartinezPicado2"><label>43</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Martinez-Picado</surname><given-names>J</given-names></name><name><surname>Mart&#x000ed;nez</surname><given-names>MA</given-names></name></person-group>
<year>2008</year>
<article-title>HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: a view from the clinic and ex vivo.</article-title>
<source>Virus Res</source>
<volume>134</volume>
<fpage>104</fpage>
<lpage>123</lpage>
<pub-id pub-id-type="pmid">18289713</pub-id></element-citation></ref><ref id="pone.0018204-Smith1"><label>44</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Smith</surname><given-names>RJ</given-names></name><name><surname>Okano</surname><given-names>JT</given-names></name><name><surname>Kahn</surname><given-names>JS</given-names></name><name><surname>Bodine</surname><given-names>EN</given-names></name><name><surname>Blower</surname><given-names>S</given-names></name></person-group>
<year>2010</year>
<article-title>Evolutionary dynamics of complex networks of HIV drug-resistant strains: the case of San Francisco.</article-title>
<source>Science</source>
<volume>327</volume>
<fpage>697</fpage>
<lpage>701</lpage>
<pub-id pub-id-type="pmid">20075214</pub-id></element-citation></ref><ref id="pone.0018204-Ghosn1"><label>45</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ghosn</surname><given-names>J</given-names></name><name><surname>Pellegrin</surname><given-names>I</given-names></name><name><surname>Goujard</surname><given-names>C</given-names></name><name><surname>Deveau</surname><given-names>C</given-names></name><name><surname>Viard</surname><given-names>JP</given-names></name><etal/></person-group>
<year>2006</year>
<article-title>HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time.</article-title>
<source>AIDS</source>
<volume>20</volume>
<fpage>159</fpage>
<lpage>170</lpage>
<pub-id pub-id-type="pmid">16511408</pub-id></element-citation></ref><ref id="pone.0018204-Bartlett1"><label>46</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bartlett</surname><given-names>JA</given-names></name></person-group>
<year>2002</year>
<article-title>Addressing the challenges of adherence.</article-title>
<source>J Acquir Immune Defic Syndr</source>
<volume>29</volume>
<issue>Suppl 1</issue>
<fpage>S2</fpage>
<lpage>10</lpage>
<pub-id pub-id-type="pmid">11832696</pub-id></element-citation></ref><ref id="pone.0018204-Murray1"><label>47</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Murray</surname><given-names>JM</given-names></name><name><surname>Emery</surname><given-names>S</given-names></name><name><surname>Kelleher</surname><given-names>AD</given-names></name><name><surname>Law</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><etal/></person-group>
<year>2007</year>
<article-title>Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase.</article-title>
<source>AIDS</source>
<volume>21</volume>
<fpage>2315</fpage>
<lpage>2321</lpage>
<pub-id pub-id-type="pmid">18090280</pub-id></element-citation></ref><ref id="pone.0018204-DeJesus1"><label>48</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>DeJesus</surname><given-names>E</given-names></name><name><surname>Berger</surname><given-names>D</given-names></name><name><surname>Markowitz</surname><given-names>M</given-names></name><name><surname>Cohen</surname><given-names>C</given-names></name><name><surname>Hawkins</surname><given-names>T</given-names></name><etal/></person-group>
<year>2006</year>
<article-title>Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor gs-9137 (jtk-303) in treatment-naive and treatment-experienced patients.</article-title>
<source>J Acquir Immune Defic Syndr</source>
<volume>43</volume>
<fpage>1</fpage>
<lpage>5</lpage>
<pub-id pub-id-type="pmid">16936557</pub-id></element-citation></ref><ref id="pone.0018204-Sedaghat1"><label>49</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sedaghat</surname><given-names>AR</given-names></name><name><surname>Dinoso</surname><given-names>JB</given-names></name><name><surname>Shen</surname><given-names>L</given-names></name><name><surname>Wilke</surname><given-names>CO</given-names></name><name><surname>Siliciano</surname><given-names>RF</given-names></name></person-group>
<year>2008</year>
<article-title>Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle.</article-title>
<source>Proc Natl Acad Sci U S A</source>
<volume>105</volume>
<fpage>4832</fpage>
<lpage>4837</lpage>
<pub-id pub-id-type="pmid">18362342</pub-id></element-citation></ref><ref id="pone.0018204-Lennox1"><label>50</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lennox</surname><given-names>JL</given-names></name><name><surname>DeJesus</surname><given-names>E</given-names></name><name><surname>Lazzarin</surname><given-names>A</given-names></name><name><surname>Pollard</surname><given-names>RB</given-names></name><name><surname>Madruga</surname><given-names>JVR</given-names></name><etal/></person-group>
<year>2009</year>
<article-title>Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial.</article-title>
<source>Lancet</source>
<volume>374</volume>
<fpage>796</fpage>
<lpage>806</lpage>
<pub-id pub-id-type="pmid">19647866</pub-id></element-citation></ref><ref id="pone.0018204-Lennox2"><label>51</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lennox</surname><given-names>JL</given-names></name><name><surname>Dejesus</surname><given-names>E</given-names></name><name><surname>Berger</surname><given-names>DS</given-names></name><name><surname>Lazzarin</surname><given-names>A</given-names></name><name><surname>Pollard</surname><given-names>RB</given-names></name><etal/></person-group>
<year>2010</year>
<article-title>Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses.</article-title>
<source>J Acquir Immune Defic Syndr</source>
<volume>55</volume>
<fpage>39</fpage>
<lpage>48</lpage>
<pub-id pub-id-type="pmid">20404738</pub-id></element-citation></ref><ref id="pone.0018204-Ramratnam1"><label>52</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ramratnam</surname><given-names>B</given-names></name><name><surname>Bonhoeffer</surname><given-names>S</given-names></name><name><surname>Binley</surname><given-names>J</given-names></name><name><surname>Hurley</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><etal/></person-group>
<year>1999</year>
<article-title>Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis.</article-title>
<source>Lancet</source>
<volume>354</volume>
<fpage>1782</fpage>
<lpage>1785</lpage>
<pub-id pub-id-type="pmid">10577640</pub-id></element-citation></ref><ref id="pone.0018204-Grant1"><label>53</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Grant</surname><given-names>RM</given-names></name><name><surname>Lama</surname><given-names>JR</given-names></name><name><surname>Anderson</surname><given-names>PL</given-names></name><name><surname>McMahan</surname><given-names>V</given-names></name><name><surname>Liu</surname><given-names>AY</given-names></name><etal/></person-group>
<year>2010</year>
<article-title>Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.</article-title>
<source>N Engl J Med</source>
<volume>363</volume>
<fpage>2587</fpage>
<lpage>2599</lpage>
<pub-id pub-id-type="pmid">21091279</pub-id></element-citation></ref><ref id="pone.0018204-Coovadia1"><label>54</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Coovadia</surname><given-names>A</given-names></name><name><surname>Abrams</surname><given-names>EJ</given-names></name><name><surname>Stehlau</surname><given-names>R</given-names></name><name><surname>Meyers</surname><given-names>T</given-names></name><name><surname>Martens</surname><given-names>L</given-names></name><etal/></person-group>
<year>2010</year>
<article-title>Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial.</article-title>
<source>JAMA</source>
<volume>304</volume>
<fpage>1082</fpage>
<lpage>1090</lpage>
<pub-id pub-id-type="pmid">20823434</pub-id></element-citation></ref><ref id="pone.0018204-Weinberger1"><label>55</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Weinberger</surname><given-names>LS</given-names></name><name><surname>Burnett</surname><given-names>JC</given-names></name><name><surname>Toettcher</surname><given-names>JE</given-names></name><name><surname>Arkin</surname><given-names>AP</given-names></name><name><surname>Schaffer</surname><given-names>DV</given-names></name></person-group>
<year>2005</year>
<article-title>Stochastic gene expression in a lentiviral positive-feedback loop: HIV-1 tat fluctuations drive phenotypic diversity.</article-title>
<source>Cell</source>
<volume>122</volume>
<fpage>169</fpage>
<lpage>182</lpage>
<pub-id pub-id-type="pmid">16051143</pub-id></element-citation></ref><ref id="pone.0018204-Lassen1"><label>56</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lassen</surname><given-names>KG</given-names></name><name><surname>Ramyar</surname><given-names>KX</given-names></name><name><surname>Bailey</surname><given-names>JR</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Siliciano</surname><given-names>RF</given-names></name></person-group>
<year>2006</year>
<article-title>Nuclear retention of multiply spliced HIV-1 RNA in resting CD4&#x0002b; T cells.</article-title>
<source>PLoS Pathog</source>
<volume>2</volume>
<fpage>e68</fpage>
<pub-id pub-id-type="pmid">16839202</pub-id></element-citation></ref><ref id="pone.0018204-Zhang1"><label>57</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Ramratnam</surname><given-names>B</given-names></name><name><surname>Tenner-Racz</surname><given-names>K</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Vesanen</surname><given-names>M</given-names></name><etal/></person-group>
<year>1999</year>
<article-title>Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy.</article-title>
<source>N Engl J Med</source>
<volume>340</volume>
<fpage>1605</fpage>
<lpage>1613</lpage>
<pub-id pub-id-type="pmid">10341272</pub-id></element-citation></ref><ref id="pone.0018204-Chun4"><label>58</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chun</surname><given-names>TW</given-names></name><name><surname>Justement</surname><given-names>JS</given-names></name><name><surname>Moir</surname><given-names>S</given-names></name><name><surname>Hallahan</surname><given-names>CW</given-names></name><name><surname>Maenza</surname><given-names>J</given-names></name><etal/></person-group>
<year>2007</year>
<article-title>Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus.</article-title>
<source>J Infect Dis</source>
<volume>195</volume>
<fpage>1762</fpage>
<lpage>1764</lpage>
<pub-id pub-id-type="pmid">17492591</pub-id></element-citation></ref><ref id="pone.0018204-Siliciano2"><label>59</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Siliciano</surname><given-names>JD</given-names></name><name><surname>Kajdas</surname><given-names>J</given-names></name><name><surname>Finzi</surname><given-names>D</given-names></name><name><surname>Quinn</surname><given-names>TC</given-names></name><name><surname>Chadwick</surname><given-names>K</given-names></name><etal/></person-group>
<year>2003</year>
<article-title>Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4&#x0002b; T cells.</article-title>
<source>Nat Med</source>
<volume>9</volume>
<fpage>727</fpage>
<lpage>728</lpage>
<pub-id pub-id-type="pmid">12754504</pub-id></element-citation></ref><ref id="pone.0018204-Ramratnam2"><label>60</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ramratnam</surname><given-names>B</given-names></name><name><surname>Mittler</surname><given-names>JE</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Boden</surname><given-names>D</given-names></name><name><surname>Hurley</surname><given-names>A</given-names></name><etal/></person-group>
<year>2000</year>
<article-title>The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy.</article-title>
<source>Nat Med</source>
<volume>6</volume>
<fpage>82</fpage>
<lpage>85</lpage>
<pub-id pub-id-type="pmid">10613829</pub-id></element-citation></ref><ref id="pone.0018204-Coffin1"><label>61</label><element-citation publication-type="other">
<person-group person-group-type="author"><name><surname>Coffin</surname><given-names>J</given-names></name><name><surname>Maldarelli</surname><given-names>F</given-names></name><name><surname>Palmer</surname><given-names>S</given-names></name><name><surname>Weigand</surname><given-names>A</given-names></name><name><surname>Brun</surname><given-names>S</given-names></name><etal/></person-group>
<year>2006</year>
<comment>Long-term persistance of low-level HIV-1 in patients on suppressive antiretroviral therapy. Abstract 169 13th Conference on Retroviruses and Opportunistic Infections; 5&#x02013;8 February 2006; Denver, Colorado, United States Available at <ext-link ext-link-type="uri" xlink:href="http://wwwretroconferenceorg/2006/Abstracts/28061htm">http://wwwretroconferenceorg/2006/Abstracts/28061htm</ext-link></comment>
</element-citation></ref><ref id="pone.0018204-Klopfenstein1"><label>62</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Klopfenstein</surname><given-names>R</given-names></name></person-group>
<year>1971</year>
<article-title>Numerical differentiation formulas for stiff systems of ordinary differential equations.</article-title>
<source>RCA Review</source>
<volume>32</volume>
<fpage>447</fpage>
<lpage>462</lpage>
</element-citation></ref><ref id="pone.0018204-Shampine1"><label>63</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shampine</surname><given-names>L</given-names></name><name><surname>Reichelt</surname><given-names>M</given-names></name></person-group>
<year>1997</year>
<article-title>The Matlab ODE Suite.</article-title>
<source>SIAM Journal on Scientific Computing</source>
<volume>18</volume>
<fpage>1</fpage>
<lpage>22</lpage>
</element-citation></ref><ref id="pone.0018204-Wei1"><label>64</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wei</surname><given-names>X</given-names></name><name><surname>Ghosh</surname><given-names>SK</given-names></name><name><surname>Taylor</surname><given-names>ME</given-names></name><name><surname>Johnson</surname><given-names>VA</given-names></name><name><surname>Emini</surname><given-names>EA</given-names></name><etal/></person-group>
<year>1995</year>
<article-title>Viral dynamics in human immunodeficiency virus type 1 infection.</article-title>
<source>Nature</source>
<volume>373</volume>
<fpage>117</fpage>
<lpage>122</lpage>
<pub-id pub-id-type="pmid">7529365</pub-id></element-citation></ref><ref id="pone.0018204-Sedaghat2"><label>65</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sedaghat</surname><given-names>AR</given-names></name><name><surname>Siliciano</surname><given-names>RF</given-names></name><name><surname>Wilke</surname><given-names>CO</given-names></name></person-group>
<year>2009</year>
<article-title>Constraints on the dominant mechanism for HIV viral dynamics in patients on raltegravir.</article-title>
<source>Antivir Ther</source>
<volume>14</volume>
<fpage>263</fpage>
<lpage>271</lpage>
<pub-id pub-id-type="pmid">19430101</pub-id></element-citation></ref><ref id="pone.0018204-Callaway1"><label>66</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Callaway</surname><given-names>DS</given-names></name><name><surname>Perelson</surname><given-names>AS</given-names></name></person-group>
<year>2002</year>
<article-title>HIV-1 infection and low steady state viral loads.</article-title>
<source>Bull Math Biol</source>
<volume>64</volume>
<fpage>29</fpage>
<lpage>64</lpage>
<pub-id pub-id-type="pmid">11868336</pub-id></element-citation></ref><ref id="pone.0018204-Koelsch1"><label>67</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Koelsch</surname><given-names>KK</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Haubrich</surname><given-names>R</given-names></name><name><surname>May</surname><given-names>S</given-names></name><name><surname>Havlir</surname><given-names>D</given-names></name><etal/></person-group>
<year>2008</year>
<article-title>Dynamics of total, linear nonintegrated, and integrated HIV-1DNA in vivo and in vitro.</article-title>
<source>J Infect Dis</source>
<volume>197</volume>
<fpage>411</fpage>
<lpage>419</lpage>
<pub-id pub-id-type="pmid">18248304</pub-id></element-citation></ref><ref id="pone.0018204-Zhou1"><label>68</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Siliciano</surname><given-names>JD</given-names></name><name><surname>Siliciano</surname><given-names>RF</given-names></name></person-group>
<year>2005</year>
<article-title>Kinetics of human immunodeficiency virus type 1 decay following entry into resting CD4&#x0002b; T cells.</article-title>
<source>J Virol</source>
<volume>79</volume>
<fpage>2199</fpage>
<lpage>2210</lpage>
<pub-id pub-id-type="pmid">15681422</pub-id></element-citation></ref><ref id="pone.0018204-Pierson2"><label>69</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pierson</surname><given-names>TC</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Kieffer</surname><given-names>TL</given-names></name><name><surname>Ruff</surname><given-names>CT</given-names></name><name><surname>Buck</surname><given-names>C</given-names></name><etal/></person-group>
<year>2002</year>
<article-title>Molecular characterization of preintegration latency in human immunodeficiency virus type 1 infection.</article-title>
<source>J Virol</source>
<volume>76</volume>
<fpage>8518</fpage>
<lpage>8531</lpage>
<pub-id pub-id-type="pmid">12163571</pub-id></element-citation></ref></ref-list></back></article>